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Abstract 
MicroRNAs play an important role in biological regulation. Recently miR-34a has 
been reported to regulate tumour cell cycle progression and apoptosis. However, the 
functional role of miR-34a in smooth muscle cell (SMC) differentiation from stem 
cells is yet unclear. Main objectives of this PhD project are to determine the functional 
role of miR-34a and its target genes in SMC differentiation and underlying 
mechanisms.  
Mouse embryonic stem (ES) cells were seeded on collagen coated flasks in 
differentiation medium to allow SMC differentiation. Upon analysis, miR-34a was 
significantly up-regulated during SMC differentiation. Results demonstrated that 
overexpression of miR-34a significantly promoted SMC-specific gene expression, 
while knockdown of miR-34a inhibited expression of SMC specific gene. Enforced 
expression and knockdown of miR-34a in differentiating ES cells up-regulated and 
down-regulated, respectively, several SMC transcription factors in a similar manner. It 
was also found that miR-34a overexpression in stem cells promoted SMC 
differentiation in vivo. Furthermore, deacetylase sirtuin 1 (Sirt1) was identified as one 
of the top targets of miR-34a. Surprisingly, Sirt1 was demonstrated to be positively 
regulated by miR-34a during SMC differentiation in a cellular context and RNA 
sequence dependent manner.  
VIII 
 
Mechanistically, the data suggested that miR-34a promoted differentiating stem cells 
arrest at G0/G1 phase, and a significant decreased incorporation of miR-34a and SirT1 
RNA into Ago2-RISC complex was observed upon SMC differentiation. The results 
demonstrated that Sirt1 acted as a transcriptional activator in the regulation of SMC 
gene during ES cell differentiation. Finally, H3K9 tri-methylation around the 
promoter regions of the SMαA and SM22α genes was also found to be significantly 
inhibited by SirT1 overexpression.  
These findings suggest that miR-34a plays an important role in SMC differentiation 
from ES cells. Meanwhile, Sirt1 can be regulated by miR-34a through an unexpected 
pathway and it was identified as a functional modulating target in miR-34a mediated 
SMC differentiation.  
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CHAPTER 1 Introduction and background 
 
1.1 Introduction 
Regenerative medicine and tissue engineering are an rapid developing field with the 
ultimately goal to repair, replace, or regenerate cells, tissues, or organs that are lost or 
damaged due to disease, injury, or ageing. Recent advances in this field have been 
greatly influenced by better understanding in multiple areas, including stem cell 
biology, tissue turnover and replacement in adult mammals, and embryonic 
development. Pluripotent stem cells including embryonic stem (ES) cells have been 
under intensive investigation for using in regenerative medicine because they hold 
significant potential for clinical therapies due to their distinctive capacity to both 
unlimited self-renew and differentiate into a wide range of specialized cell types, 
including vascular endothelial cells (Zeng et al., 2006, Xiao et al., 2006) and smooth 
muscle cells (SMCs)(Xiao et al., 2007, Xiao et al., 2012, Pepe et al., 2010, Huang et 
al., 2013). SMCs are major component of blood vessel wall and responsible for 
structure and contract ability of healthy blood vessel. Furthermore, SMC 
differentiation is a critical process during cardiovascular system development, and 
such differentiation is also involved in SMC proliferative related cardiovascular 
diseases, such as atherosclerosis and hypertension. Therefore, understanding the 
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transcriptional regulatory circuitry of SMC differentiation is fundamental to 
understanding human cardiovascular system development and realizing the 
therapeutic potential of these cells. However, the detailed molecular mechanisms of 
SMC differentiation from stem cells have not been fully clarified. 
 
MicroRNAs (miRNAs) are highly conserved, endogenous, short non-coding RNAs 
(usually contains 22 nucleotides). miRNAs have been recently identified in almost 
all species and recognized as important biological regulators in tissue development, 
cellular homeostasis, and diseases. The “classical” thinking of miRNAs’ function is 
that mature miRNAs work together with RNA-induced silencing complex (RISC), to 
suppress their target genes expression by inducing mRNA cleavage, mRNA decay or 
by inhibiting mRNA translation (Bagga et al., 2005, Giraldez et al., 2006, Filipowicz 
et al., 2008). However, recent studies suggested that instead of repression, miRNAs 
can up-regulate their target genes expression under specific circumstance (Vasudevan 
et al., 2007, Vasudevan et al., 2008). Importantly, Landgraf et al. (2007) reported that 
miRNAs are expressed in a tissue specific manner, indicating that miRNAs may play 
an important role in cell/tissue specification. Studies also suggest that miRNAs are 
involved in ES cells regulation, cardiovascular development and SMCs 
differentiation and proliferation. Dicer and Drosha are two rate-limiting enzymes 
involved in miRNA biogenesis. Murchison et al. (2005) and Wang et al (2007) 
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demostrated that miRNAs play critical roles in stem cell self-renewal and 
differentiation by disrupting Dicer or Drosha expression. Loss of miRNAs in 
Dicer-deficient mice caused severe impairment of heart and blood vessel 
development, indicating the significane of miRNAs in cardiovascular development 
(Yang et al., 2005). In addition, Albinsson et al. (2010) further highlighted the 
importance of miRNAs in SMC growth, differentiation and function by pointing out 
that deletion of Dicer in vascular smooth muscle leaded to decreased SMC 
proliferation and differentiation, and caused thinner vessel walls, impaired 
contractility and hemorrhage due to the global loss of miRNAs in vascular smooth 
muscle. However the exact role of individual miRNAs in SMC differentiation from 
ES cell remains to be further investigated.  
 
This project demonstrates for the first time that miR-34a play an important role in 
mouse and human ES cell differentiation towards SMC lineage in vitro and in vivo. 
More important, data from this project suggests that instead of repression, miR-34a 
positively regulates its target gene deacetylase sirtuin 1 (SirT1), which has been 
identified as a potential transcriptional activator of SMC genes in this project. 
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1.2 Stem cell 
Stem cells have the ability to unlimited self-renew and undergo differentiation into 
various cell lineages (also known as pluripotent). Pluripotent stem cells have been 
under intensive study in the past years, because they hold great promise to be used as 
the critical tool in regenerative medicine and tissue engineering, for clinical cell 
therapy to treat current devastating and incurable diseases, such as type 1 diabetes, 
blindness, damaged articular cartilage, neurological diseases and terminal 
cardiovascular diseases. Also, stem cells provide a tractable, manipulable and 
cost-efficiency in vitro cell culture experimental system for researchers to study 
tissue development, genetics, pathology and physiology, due to their nearly unlimited 
sources (self-renew) and pluripotency, as compared with more expensive, hard to 
obtained in vivo materials. 
 
1.2.1 Categorization of stem cells 
Currently, stem cells are categorized in to three groups based on their sources: 
embryonic stem cells, adult stem cells and induced pluripotent stem cells (iPSCs) 
(Evans and Kaufman, 1981, Takahashi and Yamanaka, 2006). Adult stem cells, also 
known as somatic stem cells (SSCs), are “partially” pluripotent stem cells that found 
in tissues and organs, including skin, brain, bone marrow, intestine and neural tissue. 
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SSCs are primarily involved in maintaining and repairing/regenerating specific tissue, 
and under certain circumstances they may be involved in diseases development 
(Phinney and Prockop, 2007). SSCs used for potential stem cell therapy are 
autologous, as they are usually harvested from the patients hence there is almost no 
immunologic barriers. However, unlike ES cells, the pluripotency of SSCs is limited 
due to the fact that they are lineage commitment, which means they only hold the 
capacity to differentiate into specific cell lineages from given germ layer based on 
their origins. Furthermore, SSCs are limited in quantity due to their lower capacity to 
divide during in vitro culture. Evidently, some specific SSCs are hard to obtain from 
patients (Barrilleaux et al., 2006, Pittenger et al., 1999). 
 
 In 2006, Takahashi and Yamanaka (2006) reported that by transducing four key 
transcription factors: OCT4, SOX2, c-Myc and KLF4 into mouse somatic cells such 
as adult fibroblasts, these cells can exhibit the morphology and growth properties of 
ES cells, as well as expressing ES cell marker genes, designated as iPSCs. iPSCs 
were then successfully generated from human somatic cells by transduction of same 
transcription factors since 2007 (Takahashi et al., 2007, Park et al., 2008). Further 
analysis demonstrated that iPSCs not only expressed pluripotent markers, but also 
have the similar function of ES cells and hold the ability to differentiate into cell 
types from three germ layers, and contribute to embryonic development (Maherali et 
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al., 2007, Takahashi et al., 2007, Takahashi and Yamanaka, 2006). Since then, several 
studies have reported refined process of reprogramming iPSCs, including adjust 
transcription factors and add extra enhancers (Park et al., 2008, Huangfu et al., 2008, 
Judson et al., 2009). 
 
The recent achievements in charactering the full potentials of various iPSCs 
generated by using different techniques have advanced one step closer to 
patient-specific cell therapy of diseases, and construct in vitro models of specific 
human tissue development and diseases, especially for the cases where animal 
models cannot fully represent human models (Puri and Nagy, 2012). Patient-specific 
iPSCs generation means there is highly reduced immunologic barriers and ethical 
issues. Also, compared with SSCs, the materials for generating iPSCs are easier to 
obtain from patients. However, despite the advantages of iPSCs and the rapid 
development of iPSCs research area, there are still some concerns regarding the 
function or application of iPSCs. Although iPSCs do share similar pluripotent and 
other properties as ES cells, the understanding of iPSCs is still far from complete, 
including the mechanism of reprogramming and characterization of iPSCs (Puri and 
Nagy, 2012). Furthermore, the success rate of generating iPSCs was still low 
(Takahashi and Yamanaka, 2006), and iPSCs displayed a lower efficiency in 
neuroepithelia differentiation, as compared with ES cells (Hu et al., 2010). Also, 
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another major concern of iPSCs in clinical therapy is their tumorigenicity, as 
suggested by some studies (Knoepfler, 2009). 
 
1.2.2 Embryonic stem cells 
ES cells are pluripotent stem cells derived from inner cell mass of blastocyst, an 
early stage embryos approximately 3.5 days post coitum (Figure 1). Mouse ES cells 
were first isolated in 1981, and their pluripotency was demonstrated by their 
contributions to all the tissue developments in mice after injecting isolated ES cells 
back into host blastocysts (Evans and Kaufman, 1981, Martin, 1981, Bradley et al., 
1984). After seventeen years, human ES cells were isolated in 1998 (Thomson et al., 
1998). The isolation of ES cells have dramatically benefit researches in tissue 
development and regenerative medicine in the past years, due to the facts that ES 
cells have almost an unlimited self-renew potential and are capable of differentiating 
into all cell types from all the three germ layers (Figure 1).  
 
As self-renew and pluripotency are the important features of ES cells, the first 
challenge in ES cells based research is to understand the mechanism by which 
controls self-renew and pluripotency of ES cells. Mouse ES cells were initially 
cultured and maintained with mouse embryonic fibroblasts (MEFs), which indicated 
that MEFs may provide the essential factors to maintain the undifferentiated ES cells. 
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Later several studies revealed that MEFs feeder-cell-derived leukemia inhibitory 
factor (LIF) is the critical factor in maintaining ES undifferentiated ES cells 
(Williams et al., 1988, Smith et al., 1988, Stewart et al., 1992). A more recent study 
by Ying et al. (2003) pointed out that bone morphogenetic protein (BMP4) can 
replace serum in the presence of LIF, to support ES cell cluture. LIF is a soluble 
glycoprotein of interleukin (IL)-6 family of cytokines, and functions through regulate 
signal transduction and activation of transcription 3 (STAT3) with gp130 signaling 
complex (Niwa et al., 1998, Matsuda et al., 1999, Wobus and Boheler, 2005). BMP4 
support undifferentiated ES cells via Smad activation and inductions of 
helix-loop-helix Id factors (Keller, 2005). More recent studies showed that three 
transcription factors: Nanog, OCT3/4 and SOX2 are key factors that control self–
renew and pluripotency of ES cells (Mitsui et al., 2003, Chambers et al., 2003, Niwa 
et al., 2000). OCT3/4 and SOX2 can form a complex that suppresses expression of 
Cdx2, and OCT4 is reported to interact with BMP4 pathway (Niwa, 2007, Wang et 
al., 2012, Niwa et al., 2005). Nanog is suggested to inhibit primitive endoderm and 
mesoderm differentiation through regulating Gata6 and brachrury, respectively, and 
study showed that Nanog is downstream effector of LIF-STAT3 pathway (Mitsui et 
al., 2003, Suzuki et al., 2006, Pan and Thomson, 2007, Nishikawa et al., 2007). More 
important, OCT3/4, Nanog and SOX2 can bind to each other’s promoter so that they 
form a core network to regulate ES cells, which involving various signal pathways 
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(Pan and Thomson, 2007). 
 
OCT3/4, SOX2 and Nanog play important roles in regulating self-renew and 
pluripotency of ES cells, and they are usually referred as stem cell undifferentiated 
markers. Regulation of undifferentiated ES cells is controlled by a complex network, 
and studies also revealed more ES cells regulator/markers, such as KlF-4, SSEA-1, 
SSEA-3/4 and GCTM-2 (Solter and Knowles, 1978, Henderson et al., 2002, Zhang et 
al., 2010, Reubinoff et al., 2000). Although OCT3/4, SOX2 and Nanog are expressed 
in both mouse and human ES cells, their functions and signal pathways may be 
slightly different in these of ES cells. Furthermore, some of the stem cell makers, 
such as SSEA-1, only expressed in mouse ES cells, while some others (e.g. 
SSEA-3/4) are detected in human ES cells (Wobus and Boheler, 2005).  
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Figure 1 Stem cell hierarchy depicting the development from Zygote to Organs. 
ES cells are isolated from ICM at blastocyst stage. ICM develops into three primary 
germ layers: ectoderm, mesoderm and endoderm, as well as primordial germ cells 
(PGC). Specific progenitor cells are derived from relative germ layers, and further 
differentiate into various types of somatic cell, which form the organs(Wobus and 
Boheler, 2005).  
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1.2.3 ES cell culture 
Two methods are commonly used for in vitro ES cell culture: ES cells are either 
cultured with feeder cells (in most of the case, MEFs are used as the feeder), or 
cultured on protein matrices with defined culture medium combined with LIF, Fetal 
bovine serum (FBS) and/or BMP4. ES cells cultured with inactive MEFs are the 
“traditional” way of maintaining undifferentiated ES cells. As mentioned earlier, 
MEFs can secrete factors that maintain undifferentiated ES cells; they also provide 
mechanical support for ES cell growing. ES cell cultured with MEFs is a well refined 
method and the outcome has been well validated in the past years (Williams et al., 
1988, Stewart et al., 1992). However, it requires additional routinely maintaining of 
MEFs in the lab, and raise the risk of MEFs contamination. Another method is 
culturing ES cells on protein matrices (gelatin is well commonly used as the base 
layer), and use defined medium in supplemented with recombinant LIF and FBS, 
without feeder layer. Maintaining mouse ES cells in feeder free condition has 
achieved great success over the past years with the presence of LIF. On the other 
hand, LIF is not sufficient for maintain human ES cells (Daheron et al., 2004, 
Humphrey et al., 2004). Human ES cells feeder free culture was reported by using 
MEF conditioned medium in 2001, although it is more complex than culturing mouse 
ES cells and usually requires basic Fibroblast Growth Factor (Xu et al., 2001, Amit et 
al., 2000). As compared with culturing on MEFs, the feeder-free culture method 
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requires less work to maintain ES cells and reduces the risk of contamination. 
However, it has some drawbacks. The culture medium must be well defined to ensure 
that it provide essential components to inhibit ES cell differentiation and support cell 
growing. This method usually requires presence of FBS to provide nutrients for ES 
cells; however the constituents of FBS are not fully defined, even after screening, 
which potentially induces differentiation. Even though mouse ES cell feeder free 
culture is well established, human ES cell culture in feeder free condition may not be 
as efficiency as culturing with MEFs and the cost of human ES cell feeder free 
culture is relatively high due to the requirements on the medium and supplements.   
 
1.2.4 ES cell differentiation in vitro 
ES cells are regulated by a complex, “balanced” network to maintain their 
pluripotency through various signal pathways, and the mechanism has been under 
intensive study since ES cells were discovered. Compared with the understanding on 
maintaining pluripotency, ES cell differentiation, especially the mechanism and 
process, is still poorly defined. Withdraw of factors that maintain their stem cell 
function in cell culture, for example removal of LIF in mouse ES cell culture, usually 
triggers ES cell differentiation. However, ES cell differentiation is induced by a 
variety of stimulations, such as growth factors, extracellular matrix, mechanical 
stress and chemical stimulations (Niwa, 2007, Nishikawa et al., 2007). 
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Understanding ES cell differentiation in vitro and in vivo has always been a major 
challenge in stem cell research. 
 
Currently, there are at least three common used approaches to induce ES cell 
differentiation in vitro: embryoid-body (EB) culture, feeder-cell culture and 
extracellular matrix proteins culture, and each method has its own advantages and 
drawbacks (Figure 2).  
 
EB culture 
The concept of EB culture is to mimics in vivo germ layer formation from ICM and it 
was first used in 1975 for teratocarcinoma cells differentiation (Martin and Evans, 
1975). EB culture was then used on ES cell differentiation from 1985 by several 
studies (Doetschman et al., 1985, Keller, 1995). In EB culture, supplements that 
maintaining pluripotency of ES cells were removed, and ES cells were allowed to 
aggregate and develop into three dimensional colonies known as EBs. EBs contains 
visceral endoderm in the outlayer with primitive ectoderm derived linages inside, 
although the structures of EBs are far less organized than actual in vivo embryo. 
Most of the cell lineages including neuronal and mesoderm lineages, as well as germ 
cell precursors can be induced by EB culture, as reviewed by Nishikawa et al. (2007). 
EB culture is the most similar representation of in vivo ES cell differentiation model, 
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and providing one of the best systems for some researches, i.e. in tissue development 
area. The initial induction of ES cell differentiation by EB culture is relatively easy, 
however it is extremely difficult to conduct guided differentiation in EB culture, and 
monitoring of cell behavior is tricky due to their 3D structure. Also, EB culture is 
quite time-consuming, as compared with other two methods. 
 
Feeder-cell culture 
Similar to maintaining ES cells on MEFs, ES cells are cultured on selected stromal 
cells. Differentiation of ES cells is supported by the surrounding feeder cells and 
given cell culture medium. OP9 stromal cell line is one of the most commonly used 
cell line, which can induce mesoderm lineages differentiation from ES cells (Nakano 
et al., 1994). The guided/selective differentiation in this method is slightly easier 
compared with EB culture. PA6 stromal cell line was reported to induce selective 
neuronal lineage differentiation from ES cells (Kawasaki et al., 2000). The 
drawbacks of this method are that the undefined factors generated by the feeder cells 
may affected the ES cell differentiation, and it requires additional maintenance of 
stromal cells. Furthermore, sometimes it is difficult to isolate differentiated ES cells 
from stromal cells. Even through guided differentiation is theoretically possible in 
this method; it still remains as a challenge. 
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Extracellular matrix proteins culture 
In this method, ES cells are cultured in a monolayer of selected extracellular matrix 
proteins (also known as substrates) with highly refined cell culture medium and 
supplements (Nishikawa et al., 1998). In order to conduct guided ES cell 
differentiation, the culture medium usually contains defined supplements which 
potentially induce specific cell lineages differentiation, and the selection of substrates 
is critical for guided ES cell differentiation. This method minimum the influence of 
neighboring differentiating cells from EB culture, as well as that from stromal cells. 
The highly defined cell culture conditions are critical for investigating signal 
pathways. Furthermore, it is up to now the best method to induce selective ES cell 
differentiation and obtain high purity of specific differentiated cell types. Once the 
differentiation model is established, it is relatively easy to use such a model study the 
molecular mechanisms of cell differentiation with high reproducibility. It has been 
reported that ES cells can differentiate into smooth muscle cells and endothelial cells 
by using this method, respectively (Xiao et al., 2006, Luo et al., 2013). However, it 
has its own drawbacks. Establishing the specific differentiation model is a huge 
challenge, which requires continuing studies in this field and multiple repeated trials 
to ensure its efficiency. As a result, the numbers of specific ES cell differentiation 
induced by this method are still limited. Although the cell culture conditions are the 
most defined among these three methods, it still cannot fully eliminate the undefined 
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factors involved in the differentiation, such as that from FBS or subsequent changes 
of the cells. The requirements for culture medium is very high, as well as the 
supplements, which may significantly increase the cost. 
 
With the recent development of engineering and material fields, more new 
techniques are used in maintaining undifferentiated stem cell, or inducing 
differentiation. For example, with the fast growing nano-technology, it has been 
reported that surface nanotopography has significant impact on stem cell self-renew 
and differentiation (Bae et al., 2014, Chen et al., 2012). Combining these new 
techniques with currently stem cell culture system will surely push forward the 
understanding in this field.   
 
 
Figure 2 Three commonly used approaches for ES cell differentiation in vitro. 
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There are three commonly used methods to induce ES cell differentiation in vitro. In 
EB culture (left) ES cells are allow to aggregate into embryo like EBs. Method using 
Feeder-cell (middle) cultured ES cells on selected stromal cells. While in 
extracellular matrix culture (right) ES cells are culture on substrates under highly 
defined conditions (Nishikawa et al., 2007). 
 
 
1.3 SMCs and their differentiation from stem cells 
1.3.1 Smooth muscle cell 
Smooth muscle is an involuntary non-striated muscle and it can be found from 
various locations of human body, such as blood vessel walls, lymphatic vessels, 
bladder, uterus and skins. Smooth muscle cells located in blood vessels, such as in 
large and small arteries and veins, are usually termed as vascular smooth muscle cells 
(VSMCs). 
 
Initially derived from mesoderm, mature VSMCs originate from various sources of 
progenitors. VSMCs provide structural integrity and contribute to contraction and 
relaxation of the blood vessels, which alter blood vessel diameter. They also 
contribute to adjust blood flow and blood pressure. Unlike other muscle cells, 
VSMCs are not terminally differentiated in human tissues (Velican and Velican, 
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1980). VSMCs can switch between contractile and synthetic phenotypes, with 
different morphology, proliferative ability, migration properties and expression levels 
of SMC gene markers. 
 
Besides providing structural and functional support to blood vessels, VSMCs 
proliferation, migration and differentiation from stem/progenitor cells are found to 
play an important role during vessel remodeling, post vascular injury and diseases, 
such as atherosclerosis (Owens et al., 2004, Ross, 1999, Xu, 2006). With the 
advanced in tissue engineering, VSMCs hold the potential ability to reconstruct 
human vascular tissue for clinical treatment. However, the limited lifespan of 
VSMCs may become the barrier for the cell therapy applications. Thus, better 
understanding of SMC differentiation from stem cell will benefit the recognition of 
diseases, tissue development and clinical tissue engineering applications. 
    
1.3.2 SMC differentiation from stem cell in vitro 
Several in vitro SMC differentiation model have been established to study the 
process of SMC differentiation from stem cells, and/or obtain functional SMCs (Xie 
et al., 2011, Xiao et al., 2010). P19 cell line was reported to have similar mechanism 
and features to ES cells for differentiation (Rideg et al., 1994). It has been reported 
that expose P19 cells to retinoic acid (RA) for 48 hours or treat with dimethyl 
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sulfoxide (DMSO) can induce these cell differentiate into fibroblast-like cells. The 
differentiated cells express SMC marker SMαA, and study also showed that they 
respond to angiotensin II and endothelin (Drab et al., 1997, Sinha et al., 2004). A404 
cells, which are derived clonal cell line from P19 but have been genetically modified 
by harboring a SMαA promoter/intron-driven puromycin resistance gene (Manabe 
and Owens, 2001). Exposing these cells to all-trans RA (atRA) can induce SMC 
differentiation. More importantly, the differentiated SMC-like cells can be sorted out 
due to the presence of puromycin resistance gene, and results suggested that more 90% 
of cells express SMC markers, such as SMαA, calponin or smooth muscle myosin 
heavy chain (SM-MHC)(Manabe and Owens, 2001, Spin et al., 2004). Although P19 
and A404 cell lines have similar differentiation ability to ES cells, and they have 
been successfully demonstrated to differentiate into SMC-like cells. However they 
are not “pure” ES cells.  A404 cell lines are genetic modified with SMαA promoter 
and purmycin resistance genes, thus using these models is inappropriate for studying  
the mechanism of SMC differentiation from original ES cells. Furthermore the 
differentiation ratio from P19 cell line was reported very low (Manabe and Owens, 
2001, Xie et al., 2011). 
 
Mouse ES cells have been reported to differentiate into SMCs by using EB culture. 
After EB formation they were treated with atRA and dibutyryl-cAMP, and results 
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suggested that 67% of the cells in the EBs express SMC-like features, compared with 
10% in the control group (Drab et al., 1997, Sinha et al., 2004). EB culture can also 
be used in SMC differentiation from human ES cells. CD34+ vascular progenitor 
cells isolated from human ES cells can differentiate into SMC-like cell with 
treatment of platelet-derived growth factor-BB (PDGF-BB). These SMC-like cells 
express SMαA, SM-MHC, SM22α and calponin. However, they also express some 
endothelial markers (Ferreira et al., 2007, Xie et al., 2007, Xie et al., 2011). 
 
Recent studies also reported that SMC differentiation from stem cell can also be 
achieved by using substrates culture combined with defined culture medium and 
supplements. ES cells cultured on a monolayer and treated with atRA were induced 
to SMC differentiation, and up to 65% of cells expressed SM-MHC. They also 
express other SMC makers, as well as some SMC functions, such as contraction 
response to muscarinic agonist carbachol (Huang et al., 2006, Xie et al., 2009). ECM 
protein collagen type IV is also reported to induce SMC differentiation from stem 
cells. VEGFR2+ progenitor cells derived from human ES cells cultured on collagen 
type IV in the presence of PDGF can lead to SMC differentiation (Yamashita et al., 
2000, Sone et al., 2003). Xiao et al. (2007) reported that ES cells can differentiate 
into SMCs by using ECM protein collagen type IV. ES cells were cultured on 
collagen type IV coated cell culture flaks or dishes and over 50% of the cells were 
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SMαA positive cells after 6 days. Furthermore, stem cell antigen-1 positive (Sca-1+) 
cells were isolated from ES cells cultured on collagen type IV coated flasks for 3 to 4 
days, and cultured with or without PDGF-BB for 6 to 90 days. Data revealed that a 
highly purified SMCs (>95%) expressed high SMC markers, but not endothelial 
cell-specific markers, after 30 days of treatment.  
 
In summary, different methods for SMC differentiation from stem cells, with the aim 
to study the mechanism and/or obtaining highly purified SMCs for potential cell 
therapy have been reported in several studies, although each model has its own 
advantages and drawbacks. RA/atRA and collagen type IV are reported to induce 
SMC differentiation in many studies, as combined with supplements, such as PDGF 
or dibutyryl-cAMP.  
 
1.3.3 Mechanisms of SMC differentiation from stem cell 
SMC differentiation from stem cell is a complex process, which is governed by a 
interacting network, including EMC proteins and intergrins, suerm response factors 
(SRF) and myocardin complex, reactive oxygen species, histone deacetylases, 
retinoid receptors , PDGF, and TGF family and others (Xiao et al., 2010). 
Furthermore, SMCs is derived from various sources in vivo, and they can undergo 
phenotype switching under certain conditions, which make it very difficult to define 
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“terminated differentiation” in SMCs. Regardless of progress made in understanding 
SMC differentiation in this field, the underlying mechanism is still poorly defined. 
 
As suggested by several studies, collagen plays an important role in SMC 
differentiation from stem cell. ECM is a complex tissue surrounding the cells and 
providing structural support as well as other important functions, such as 
differentiation (Lozito et al., 2009). Collagen is one of the most important 
components of ECM, which containing more than 16 different members. Among 
them, collagen I, II and III can form fibrils similar structure and collagen IV is 
widely found in basal lamina (Rozario and DeSimone, 2010). Collagen induced SMC 
differentiation from stem cell is suggested to go through collagen type IV-integrin 
and PDGFRβ mediated signaling pathways (Xiao et al., 2007). In their study, high 
levels of integrin α1, αv, β1 and β3 were expressed in SMCs derived from ES cells, 
as well as Sca-1+ progenitor cells. Inhibition of integrin function and blocking 
antibodies against integrin α1, αv and β1 significantly inhibited SMC differentiation 
from stem cells. Interestingly, PDGF-BB is a well-known SMC differentiation 
inducer (Sone et al., 2003, Yamashita et al., 2000), but the effect of exogenous 
PDGF-BB is weak on SMC differentiation induced by collagen IV. However, 
inhibition of PDGF receptor significantly inhibits SMC differentiation. The 
downstream signal pathways of integrin which were activated by collagen IV in 
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SMC differentiation include focal adhesion kinase, paxillin, phosphatidylinositol 
3-kinase (PI3-kinase) and PDGFRβ(Xiao et al., 2007). 
 
TGF-β plays a critical role in activating SMC differentiation (Hirschi et al., 1998). 
TGF-β, PDGF-BB and ECM proteins and their secretions can activate NADPH 
oxidase 4 (Nox4), which further triggers a variety of downstream signal pathways 
(Xiao et al., 2009, Xie et al., 2011). Activated Nox4 generate reactive oxygen species 
(ROS), which further generate H2O2  and O2
−  (Deliri and McNamara, 2007, 
Sumimoto et al., 2005). H2O2  up-regulates SRF expression as well as 
phosphorylation. SRF can bind to CArG region of SMC gene promoter(s), where it 
recruits its co-activator myocardin to regulate SMC gene expression (Wang et al., 
2003, Wang et al., 2004). On the other hand, O2
− increased SRF-mediated SMC 
gene transcription activation through MAPK pathway in SMC differentiation (Xiao 
et al., 2009)(Figure 3). More recently, studies suggest that nuclear factor erythroid 
2-related factor (Nrf3) can up-regulate Nox4 to generate more ROS to enhance SMC 
differentiation (Pepe et al., 2010, Xiao et al., 2012). 
 
Histone modification is another important player in SMC differentiation (Tang et al., 
2012, Lunyak and Rosenfeld, 2008), and methylation and acetylation are the two 
main forms of histone modification. Histone acetyl transferases (HATs) and histone 
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decaetylases determine the acetylation state of histone. Histone modification was 
first connected with SMC phenotype switching (McDonald et al., 2006, Xie et al., 
2011). However, recently studies reported that spliced HDAC7 increase the binding 
between SRF and CArG region of SMC genes, by which it up-regulates SMC 
differentiation genes (Margariti et al., 2009). 
 
Current studies have discovered, not all, but party of the factors that controlling the 
complex SMC differentiation. However, the importance of miRNAs in biological 
regulation has been rapidly recognized in the past years, and their functional role in 
SMC differentiation, is still largely unknown.  
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Figure 3 Role of Nox4 and signal pathways in SMC differentiation 
Activated Nox4 by TGF-β or other factors generates ROS. H2O2 up-regulates SRF 
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and enhance SRF phosphorylation. Phosphorylated SRF binds to promoter region of 
SMC genes and work together with its co-activator myocardin to regulate SMC 
differentiation. 𝐎𝟐
− triggers p38MAPK pathways to increase SRF-mediated gene 
transcription activation, further enhance SMC differentiation(Xiao et al., 2010). 
 
1.4 MicroRNA 
miRNAs were first found in C. elegans by Lee et al(1993), and then rapidly 
identified in almost all species. According to version 21 of miRNA database 
(http://www.mirbase.org/), 2588 human miRNAs have been reported to the database, 
while 1915 mature miRNAs were found in Mus musculus. In the past years miRNAs 
have been reported to play an important role in various biological processes and 
diseases, such as cardiogenesis, cancer or atherosclerosis.  
 
1.4.1 miRNA biogenesis 
miRNAs are endogenous, highly conserved short non-coding RNAs (usually 
contains 22 nucleotides). Initially, most of the miRNAs are transcribed by RNA 
polymerases II (RNA Pol II) from independent miRNA genes, polycistronic 
transcripts that often encode multiple related miRNAs, or from introns of protein 
coding genes. miRNA transcription is controlled by RNA PoL II related transcription 
27 
 
factors and epigenetic regulators (Cai et al., 2004, Lee et al., 2004). However, it has 
been reported that some miRNAs are transcribed by RNA Pol III (Pfeffer et al., 
2005). The initial transcription generates a long (usually over 1kb) primary miRNA 
(pri-miRNA), which has a stem-loop structure containing mature miRNA sequences. 
Within the nucleus, the pri-miRNA is processed by ribonuclease III (RNase III) type 
endonuclease Drosha formed complex. The~160kDa nuclear protein, Drosha, acts 
specifically on double-stranded RNA (dsRNA). Drosha can directly cleave the 5’ and 
3’ arms of the pri-miRNA hairpin, and it works together with its essential co-factor 
DiGeorge syndrome critical region gene 8 (DGCR8)/Pasha for processing the 
pri-miRNA (Han et al., 2004, Han et al., 2006). DGCR8 contains 2 dsRNA-binding 
domains (dsRBDs) which recognize pri-miRNA, while its C terminus interacts with 
Drosha. Drosha and DGCR8 form a complex called Microprocessor, which 
cleavages the stem-loop of the pri-miRNA to generate a small hairpin-shaped RNA 
with approximately 65 nucleotides in length, called pre-miRNA (Lee et al., 2003, 
Yeom et al., 2006, Han et al., 2006, Han et al., 2004). The majority of pre-miRNAs 
are generated by Drosha-DGCR8 pathway, however, it has been reported that a small 
amount of short intronic miRNAs (mirtrons) can bypass Drosha-DGCR8 pathway 
and processed into pre-miRNAs through splicing and lariat debranching enzyme 
(Okamura et al., 2007, Berezikov et al., 2007, Ruby et al., 2007).  
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Following nuclear processing, pre-miRNA is loaded into a transport complex which 
consists of Exportin-5 (XPO5) and GTP –binding nuclear protein RAN-GTP, and 
exported into the cytoplasm. GTP is hydrolysed through the nuclear pore complex 
and as the result, pre-miRNA is released into the cytosol from the disassembled 
complex (Yi et al., 2003, Ha and Kim, 2014). 
 
In the cytoplasm, the loop of the pre-miRNA is cleaved by Dicer and generates a 
small (about 20-22 nucleotides) miRNA duplex (Bernstein et al., 2001, Hutvagner et 
al., 2001). Dicer is an RNase III endonuclease of roughly 200kDa and works 
specifically on dsRNAs. In human, Dicer interacts with the double-stranded 
RNA-binding domain proteins called Tar RNA binding protein (TRBP), to form a 
complex for pre-miRNA cleavage. Although TRBP is not essential for the cleavage 
of the pre-miRNAs mediated by Dicer, it stabilizes and enhances the process 
(Chendrimada et al., 2005, Haase et al., 2005, Lee et al., 2006). Also, for 
pre-miRNAs containing a high degree of complementarity along the hairpin stem, an 
Argonaute 2 (Ago2) induced endonucleolytic cleavage step takes place before Dicer 
mediated cleavage (Diederichs and Haber, 2007, Winter et al., 2009). 
 
Once the pre-miRNA is cleaved by Dicer into small RNA duplex, it is loaded with an 
AGO protein to form the cytoplasmic effector complex called RNA – induced 
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silencing complex (RISC) (Hammond et al., 2001).  Multiple AGO protein 
homologues were expressed in mammals, named AOG1-AGO 4 respectively. RISC 
loading is suggested to be regulated by RISC loading complex (RLC), which consists 
of Dicer, TRBP, protein activator of PKR (PACT) and the core component Ago 
protein (Gregory et al., 2005, Lee et al., 2006, Haase et al., 2005). During RISC 
forming, the double-stranded miRNA duplex is separated into a functional guide 
strand (mature miRNA), and a passenger strand which is typically degraded. The 
single stranded mature miRNA is fully incorporated with active RISC and ready to 
perform gene regulation (Figure 4). However, some studies pointed out that the 
passenger strand can also be loaded with RISC and perform active miRNA function 
(Ghildiyal et al., 2010, Okamura et al., 2009). The exact mechanism by which the 
guild strand is selected is still not very clear. Current studies suggest that the guild 
strand selection is determined during AGO loading step, and may mainly base on the 
relative thermodynamic stability of the base pairs at the two ends of the duplex: the 
strand with relatively lower stability is typically selected as the guide strand 
(Khvorova et al., 2003). 
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Figure 4 Biogenesis of miRNAs 
miRNAs are transcribed by RNA Pol II/III into pri-miRNAs and processed into 
pre-miRNAs in nucleus. Pre-miRNAs are exported from nucleus and become mature 
miRNAs incorporated with RISC through several steps in cytoplasm (Winter et al., 
2009). 
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1.4.2 miRNAs Nomenclature 
The nomenclature of miRNAs and their genes is slightly inconsistent, especially at 
the time when miRNAs were initially identified in the 90s (e.g. the first known 
miRNAs, let-7 and lin-4). A more “standard” nomenclature scheme for miRNAs was 
induced later as large numbers of miRNAs were discovered (Lagos-Quintana et al., 
2001, Griffiths-Jones, 2006, AMBROS et al., 2003, Lee and Ambros, 2001). Briefly, 
mature miRNAs are named using prefix “miR” followed by a dash and unique 
identify number (e.g. miR-22). miRNA genes and precursors are also named using 
“prefix-dash-identify number” nomenclature system, except that “mir” is used 
instead of “miR” (e.g mir-22). The identify numbers are assigned sequentially, which 
indicates that a miRNA with higher identify number is likely to be discovered later 
than that with lower identify number. Although the “miR/mir - xxx” system is 
commonly used in studies, under some circumstances another 3 letters abbreviation 
is prefixed to indicate the organism, for example hsa-miR-xxx means that it is mature 
miRNA observed from human, and in the other hand mmu-miR-xxx stands for 
mouse miRNAs. However, identical miRNAs have the same identify number, 
regardless of organism. Mature miRNAs with identical structure (usually differ from 
1 -2 nucleotides) have the same identify number but annotated with an additional 
lower case letter (e.g. miR-121a and miR-121 b are closely related miRNAs). It is 
possible that completely identical mature miRNAs are generated from different 
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pre-miRNAs and/or genetic loci, which are differed by number suffixes at the end, 
e.g. mir-125b-1 and mir-125b-2 can both generate mature miR-125b. In some cases 
if two mature miRNAs are produced from opposite arms of the same pre-miRNA 
precursor, they were denoted with letter suffixe: -3p (from 3’arm) or 5p (from 5’arm). 
However, if two miRNAs are from the same miRNA precursor, the predominantly 
expressed miRNA is assigned with the name of mature miRNA, while the one from 
opposite arm is known as miRNA*. (e.g. miR-123 and miR-123*, where miR-123 
expression is much higher than miR-123* in cells) 
 
1.4.3 miRNAs regulate their target genes 
Mature miRNAs cannot regulate their target genes by themselves. Instead, they are 
incorporated into RISC in vivo and act as the “seeker” to guide RISC to their target 
mRNAs. Each mature miRNA can recognized and bind to several different target 
mRNAs through Watson-Crick base pairing. In plants, miRNAs are fully or nearly 
perfect complementary to their target mRNAs, while animal miRNAs usually 
recognize partially complementary sequences (Voinnet, 2009, Filipowicz et al., 2008). 
Thus the target recognition for animal miRNAs is more complex (Figure 5). It has 
been reported that the complementary “seed” region, which contains nucleotides 2-8 
from 5’ end of the miRNA, is critical for miRNA target recognition and gene 
regulation in animals. Also the mismatches must be located in the central region of 
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miRNA-mRNA duplex, and target mRNA should have reasonable complementarity 
to the 3’ half of miRNA to stabilize the interaction.(Filipowicz et al., 2008, 
Huntzinger and Izaurralde, 2011, Lewis et al., 2005, Grimson et al., 2007) Majority 
of the binding sites were identified on 3’UTR of the target mRNA, however some 
studies demonstrated that mature miRNAs can bind to amino acid coding sequence 
and regions in 5’UTR of target mRNA(Lytle et al., 2007).  
 
The understanding of miRNAs’ function has been remarkably advanced in the past 
few years, but the exact mechanism by which miRNAs regulate gene expression is 
still unclear, especially for the effect of individual miRNA on their target genes. The 
“classical” thinking of miRNA-target gene regulatory machinery is that miRNAs 
guide RISC to their target mRNA and suppress the genes expression. The repression 
of target gene expression induced by miRNAs is commonly divided into three 
processes: i. directly site-specific cleavage. ii. mRNA decay/degradation. iii. mRNA 
translation inhibition (Bagga et al., 2005, Giraldez et al., 2006, Filipowicz et al., 
2008). Initially, most of the discovered plant miRNAs were reported to regulate 
target gene through mRNA cleavage as a result of perfect or nearly perfect 
complementary matching, and the process is suggested to go through RNA 
interference (RNAi)-like pathways. Unlike plants, most of the animal miRNAs 
imperfectly pair with their target mRNA, and suppress their target genes expression 
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at translation level. However, more recent studies suggest that miRNAs can also 
induce mRNA degradation in animals, and conversely, in plants miRNAs can lead to 
translation inhibition (Brodersen et al., 2008, Gu and Kay, 2010, Selbach et al., 2008, 
Guo et al., 2010). Furthermore, it is still not clear that whether the target genes 
silencing induced by miRNAs is predominantly by mRNA degradation or translation 
inhibition, or combination of both pathways (Huntzinger and Izaurralde, 2011). 
Importantly, each miRNA can potentially regulate several target genes by using 
different pathways, and the regulation of target genes by individual miRNA can be 
affected by many factors, such as species, biological environment/conditions 
(Ameres and Zamore, 2013).  
 
As mentioned earlier, mature miRNAs guide RISC to the mRNAs of their target 
genes and suppress genes expression. RISC is a multiprotein complex and the exact 
constituents of RISC are still not clear. Currently the key and best characterized 
components of RISC are AGO proteins (Peters and Meister, 2007, Tolia and 
Joshua-Tor, 2007). AGO proteins not only take part in biogenesis of miRNAs, but 
also play critical roles in miRNA induced gene repression (Kiriakidou et al., 2007). 
Mammals contain four AGO proteins, namely AGO 1 to AGO 4. All of the four AGO 
proteins are involved in miRNA induced repression, but only AGO2 functions like 
RNAi to cleavage mRNA in animals. Up to now it is suggested that AGO proteins 
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interact with G182 proteins and cytoplasmic poly(A) binding protein (PABPC) to 
carry out miRNA induced gene repression (Huntzinger and Izaurralde, 2011, 
Filipowicz et al., 2008). However, the downstream pathways by which AGO proteins 
use to suppress gene expression are largely depending on specific miRNA-mRNA 
interaction and other factors, which require more investigation into this field. 
 
 
Although majority of the reported miRNAs go through the “classical” miRNA-target 
gene regulatory machinery, recent reports demonstrated that miRNA can up-regulate 
their target genes expression under certain circumstances. Vasudevan et al. (2007) 
reported that human miR-369-3 can up-regulate its target gene reporter: tumor 
necrosis factor–α(TNFα) containing AU-rich elements (AREs) under cell cycle arrest 
in HEK 293 cells. Importantly, miR-369-3 can only activate TNFα-ARE reporter 
under cell cycle arrest, and switch back to traditional repression in growing cells. 
They also conducted additional experiments by using reporters targeted by Let-7 and 
synthetic miRNA miRcxcr4, respectively, and the results pointed out that the 
reporters were up-regulated by the miRNAs under cell cycle arrest. This was the first 
time that miRNAs are reported to switch from repression to activation of its target 
gene expression. In the study Vasudevan et al. (2007) concluded the essential factors 
that lead to such up-regulation induced by miRNAs in their experiments: First, this 
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up-regulation only occurred upon cell cycle arrest at G0/1, but not other cell cycle 
phase or in growing cells. Second, presence of AREs in 3’UTR of TNFα mRNA is 
required for such activation. Third, AGO2- fragile X mental retardation–related 
protein 1 (FXR1) complex is required. In the following study, the importance of cell 
cycle arrest in mRNA induced target gene activation was further confirmed 
(Vasudevan et al., 2008). Other laboratories also reported miRNA induced expression 
of target genes. Place et al. (2008) reported that miR-373 can target promoter 
sequences of E-cadherin and cold-shock domain-containing protein C2, and induces 
their gene expression in PC-3 cells. Huang et al. (2011) reported that the promoter 
region of Cyclin B1 (Ccnb1) mRNA contains high-complementary sites for miR-744, 
and expression of Ccnb 1 can be induced by miR-744 in mouse cell line. 
Interestingly, miRNAs target the promoter regions of their target genes in these cases, 
implying that the location of the binding sites for miRNAs may also affect their 
function. Also, miR-155 was reported to directly and indirectly enhances its target 
gene TNF-α translation in macrophages (Tili et al., 2007), and miRNAs have also 
been suggested to up-regulate their target genes in immature oocytes (Mortensen et 
al., 2011). 
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Figure 5 miRNA target recognition in plants and animals 
miRNAs recognize their targets by Waston-Crick base pairing. In plants base pairing 
between miRNA and mRNA is perfect or nearly perfect, while animal miRNAs 
recognize partially complementary binding sites(Huntzinger and Izaurralde, 2011). 
 
1.4.4 Functional role of miRNAs in cardiovascular system and ES 
cell differentiation 
Accumulating evidences suggest that miRNAs play important roles in biological 
regulation of cardiovascular system development and diseases. The importance of 
miRNAs in such fields was first highlighted by inhibiting or disrupting miRNA 
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biogenesis to knockdown the “global” miRNAs level. Yang et al. (2005) generated 
Dicerex1/2 mice with two deleted essential exons for the function of Dicer, and 
reported that homozygous Dicerex1/2 died between day 12.5 and 1.45 of gestation. 
They also reported that from E11.5 Dicerex1/2  embryos displayed an impaired 
growth and development phenotype, and blood vessel formation was severely 
compromised in Dicerex1/2 embryos and yolk sacs. Another study carried out by 
Albinsson et al. (2010) pointed out that transgenic mice with deletion of Dicer in 
vascular smooth muscle resulted in late embryonic lethality at embryonic day 16 to 
17 due to decreased SMC proliferation and differentiation, which caused thinner 
vessel walls, impaired contractility and hemorrhage. These data suggest that loss of 
miRNAs due to Dicer knockout has significant impact on embryo growth and 
cardiovascular system development. With the recent achievements on understanding 
the biogenesis and function of miRNAs, now research focus on the functional role of 
individual miRNA in cardiovascular system and diseases. Small et al. (2010) 
summarized a subset of miRNAs expressed in cardiovascular system and diseases. In 
the study they highlighted the important roles of miR-1, miR-21, miR-133 and 
miR-208a in cardiomyocyte hypertrophy, miR-195, miR-199a and miR-320 in 
cardiomyocyte apoptosis and regeneration, miR-21, miR-145, miR-221 in restenosis, 
and finally miR-221 and miR-222, miR-210, miR-126 and miR-17-92 cluster in 
angiogenesis. Taken together, these data clearly indicate the important roles of 
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miRNAs from early embryo development to regulation of mature cardiovascular 
system and diseases. 
 
Stem cell differentiation plays an important role during tissue development and 
pluripotent stem cells hold significant potential for clinical therapies. SMC 
differentiation is a critical process during cardiovascular system formation and 
development, as well as SMC proliferative related cardiovascular diseases, such as 
atherosclerosis. As suggested by Landgraf et al. (2007), many miRNAs are expressed 
in a tissue-specific manner, implying that miRNAs may have significantly impact in 
cell/tissue specification. Deletion or disrupting of dicer or dorsha in ES cells lead to 
compromised stem cell self-renew and differentiation due to loss of “global” 
miRNAs, providing an overall valuation of miRNA pathways in ES cells (Murchison 
et al., 2005, Wang et al., 2007). 
 
Furthermore, many recent studies have discovered the specific functional role of 
individual miRNA in ES cell differentiation. miR-21 is a well-known ES cell related 
miRNA. It has been reported that miR-21 level increased while ES cell started to 
differentiate (Singh et al., 2008). Further analysis showed that mRNAs of SOX2 and 
Nanog have potential binding sites for miR-21. SOX2 and Nanog are key factors for 
regulating stem cell self-renewal, and their expressions were repressed by induction 
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of miR-21 under stem cell maintaining condition. Furthermore, RE1-silencing 
transcription factor (REST), a highly expressed protein in mouse ES cells, is proved 
to maintain self-renewal and pluripotency of mouse ES cells through suppressing 
miR-21 (Singh et al., 2008). Also, miR-134, miR-296 and miR-470 were found to 
target mRNAs of Nanog, SOX2 and OCT4 to induce ES cell differentiation (Tay et 
al., 2008, Gangaraju and Lin, 2009). These findings suggest that miRNAs can 
directly target the key factors that controlling ES cell differentiation, and/or acting as 
downstream pathways of other regulators. 
 
In additional to direct targeting the key genes which maintaining stem cell 
self-renewal and pluripotency, some miRNAs are also suggested to regulate stem cell 
differentiation in a more “complex and indirect” pathway, or even feedback loops. 
miR-290-295 cluster were reported to highly expressed in mouse ES cells, and 
controlled by a complex regulatory network consisting of Nanog, OCT4 and 
SOX2(Marson et al., 2008). miR-290-295 cluster were reported to regulate OCT4 
indirectly through DNA methylation. Furthermore, some studies report that 
miR-290-295 cluster can promote pluripotency of ES cells through regulation of cell 
cycle, paired-box transcription factor 6, or even promote the production of mouse 
iPSC (Sinkkonen et al., 2008, Lichner et al., 2011, Kaspi et al., 2013, Judson et al., 
2009). 
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Beside the important roles of miRNAs in maintaining self-renewal and pluripotency, 
several studies have also suggested that miRNAs are essential players in specific 
SMC differentiation, and one of the best examples are miR-143/145. Human 
miR-143/145 cluster are located on chromosome 5q33 and regulated by a common 
promoter (Iio et al., 2010). miR-143/145 are suggested to be co-transcribed as a 
bicistronic unit, and they are direct targets of SMC transcriptional factors: SRF and 
myocardin, as well as Jag-1/Notch pathway (Boucher et al., 2011, Xin et al., 2009). 
Mice lacking of miR-143/145 have minor structural and functional defect in blood 
vessels but impaired neointima formation in response to vascular injury due to defect 
SMC migratory ability (Xin et al., 2009). More importantly, miR-145 has been 
proved to induce SMC differentiation from different types of stem cells by repressing 
their self-renewal through OCT4, SOX2 and KLF4 pathways, and increase 
myocardin protein through feedback from SRF-myocardin complex formation (Xin 
et al., 2009, Cordes et al., 2009, Xu et al., 2009). While miR-143 repress 
myocardin’s competitor, Elk-1, to promote SMC differentiation (Wang et al., 2004, 
Cordes et al., 2009). 
 
Taken together, the importance of miRNAs has been well recognized since they were 
found in 1993, and the understanding of miRNAs biogenesis and functions has been 
well advanced over the last twenty years. However, the miRNA-target gene 
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regulatory machinery in stem cell differentiation is still poorly defined due to the 
limited knowledge in the complex RISC, various downstream signal pathways 
involved in stem cell differentiation and specific miRNA-mRNA interaction. Further 
investigation into the function role of miRNAs in vascular cell differentiation from 
stem cells will benefit the understanding of vascular system development and disease 
applications. 
 
 
1.5 Project Aim and objectives  
SMC differentiation from stem cells plays an important role in cardiovascular system 
development and diseases. Better understanding of the complex molecular 
mechanisms underlying SMC differentiation could contribute to our knowledge of 
tissue development, diseases and regenerative medicine, especially in the fields of 
atherosclerosis, hypertension and angiogenesis. This PhD project aims to identify the 
potential miRNA(s) involved in SMC differentiation from ES cells and investigate 
the functional role of selected miRNA(s) in SMC differentiation in vivo and in vitro, 
as well as providing a profound study of its (their) downstream signal pathways by 
which mediates stem cell differentiation towards SMCs. 
 
The objectives of this PhD project are: 
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1. Further validating the previous established collagen-based in vitro SMC 
differentiation model (Xiao et al., 2006) by using another ECM protein 
collagen type I and mouse ES cells. SMC differentiation will be assessed at 
RNA level and protein level. Furthermore, expression of ES cell makers and 
SMC transcriptional factors will also be assessed. 
2. Using well established in vitro SMC differentiation model and the relative 
information collected from literatures to perform miRNA microarrays 
analysis. Potential miRNAs involved in SMC differentiation will be initially 
screened at this step, and subjected to further confirmation from in vitro 
experiment  
3. Further confirm the results from miRNA microarrays analysis by checking 
the expression of potential miRNAs during SMC differentiation using 
Real-Time qPCR. Once the selected miRNA(s) is confirmed, perform 
gain/loss-function experiments to determine their roles in SMC 
differentiation from both human and mouse ES cells in vitro.  
4. If results from in vitro gain/loss-function experiments are satisfied, determine 
whether the selected miRNA(s) has similar role in SMC differentiation in 
vivo by using Matrigel implants in mice. 
5. Determine the potential target gene(s) for the selected miRNA(s)  
6. Further confirm the exact target gene(s) for the selected miRNA(s). The 
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target mRNA(s) for selected miRNA(s) will be assessed by using gain/loss of 
function experiments combined with luciferase reporter assay.  
7. Investigate the downstream pathways of selected miRNA(s) and its (their) 
target(s), including specific miRNA-mRNA interaction and their impact on 
SMC differentiation. 
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CHAPTER 2 Materials and Methods 
 
2.1 Cell Culture 
2.1.1 Making ES cell basic medium (BM) 
ES cell basic medium (BM) in this project is defined as KnockOut™ D-MEM 
(Gbico, Invitrogen) supplemented with 100 U/ml penicillin and 100 ug/ml 
streptomycin. BM was stored at 4°C fridge for maximum 4 weeks,  
 
2.1.2 Making  complete ES cell culture medium (CM) 
It is important to use the right culture medium for maintain ES cell to prevent 
differentiation. Complete ES cell culture medium was prepared into small amount 
(usually 50ml) and stored at 4°C fridge for maximum 8 days. To make 50ml of CM, 
5ml of Foetal Bovine serum (FBS) for stem cell (Gibco, Invirtogen) was added into 
45ml of BM, followed by adding 500µl of 100 × MEM Non-Essential Amino Acids 
Solution (MEM-NEAA, Gibco, invirtogen), 50µl Recombinant Human Leukemia 
Inhibitory Factor (LIF, 10µg/ml, Prospec) and 5µl of 1M 2-Mercaptoethanol 
(Sigma-Aldrich).  
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2.1.3 Maintaining mouse ES cell 
Mouse embryonic stem cells (ES-D3 cell line, CRL01934, ATCC, USA) were 
maintained in T25 flask with 5ml of complete ES cell culture medium (CM) in 37°C 
and 5% CO2 incubator. ES cells were passaged every 2 or 3 days when reached over 
70% confluency, and in a ratio of 1:6 to 1:10. 
 
2.1.4 Passaging mouse ES cells 
New T25 flask was coated with pre-warmed 0.04 % gelatin (Sigma-Aldrich) in PBS 
and incubated at 37° C for at least 30 minutes. After removing old medium, ES cells 
were washed with PBS then treated with trypsin-EDTA for 1mins in 37°C incubator. 
Pre-warmed CM was added into the flask to neutralize the trypsin and cells were 
dissociated into single cell suspension by pipetting up and down several times. ES 
cells were then passaged at a ratio of 1:6 to 1:10 into the pre-coated T25 flask and 
incubated in a 37° C, 5% CO2 incubator for 2 to 3 days. 
 
2.1.5 Freezing stocks of mouse ES cells 
The culture medium was removed from flasks and cells were washed with PBS once, 
and then treated with trypsin-EDTA (Sigma-Aldrich) for 1 minute in a 37°C 
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incubator. BM containing 10% FBS was added into flasks to neutralize reaction, and 
the cell suspension was transferred into a 15ml tube and spun at 1,000 × g for 5 
minutes. Supernatant was then discarded and ES cells were re-suspended in freezing 
medium (FM) consisting of 50% DMEM (Sigma-Aldrich), 40% FBS and 10% 
Dimethyl sulfoxide (DMSO; Sigma-Aldrich). The cell suspension was split into 
cryovials a ratio of 1:4, placed into a cooling container (Mr. Frosty) and placed in a 
-80°C freezer overnight. Cryovials were transferred into liquid nitrogen the next day 
for long-term storage. 
 
 
2.2 Differentiation of mESCs towards smooth muscle cells  
Cell culture flasks or plates were coated with 5ug/ml collagen I/IV in cold PBS for at 
least 2 hours at room temperature. Undifferentiated ES cells were washed with PBS, 
treated with trypsin-EDTA, dissociated into single cells and seeded onto the 
pre-coated flasks or plates, followed by cultured in SMC differentiation medium 
(DM) [MEM alpha modification (Sigma-Aldrich) supplemented with 10% FBS 
(Gibco, Invirtogen), 0.05mM 2-mecraptoethanol, 100 U/ml penicillin and 100 ug/ml 
streptomycin] for 0 to 9 days prior to further treatment. The medium was refreshed 
every other day from day 2. 
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2.3 microRNA and plasmid transfection 
2.3.1 Transfection of miRNA precursors or inhibitors  
Transfection is the process of introducing foreign nucleic acids into cells. miRNA 
precursors or inhibitors and respective miRNA negative control were transfected into 
ES cells by using  siPORT™NeoFX™ transfection agent (Ambion, Applied 
Biosystem) according to the manufacturer’s instructions. Before preparing 
transfection complexes, cells were washed with PBS, dissociated into single cell with 
trypsin-EDTA, counted by using a hemocytometer, and re-suspended in culture 
medium at the correct cell density according to Table 1, and stored in 37°C and 5%  
𝐂𝐎𝟐 incubator while transfection complex was prepared. Warm Opti-MEM (Gibco, 
Invitrogen) was mixed with warm siPORT™NeoFX™ agent by pipetting and 
incubated for 10 minutes at room temperature, while miRNA precursors or inhibitors 
and their respective negative controls (10µM, Ambion, Applied Biosystems) were 
diluted by warm Opti-MEM in other tubes. After incubation, an equal volume of 
diluted siPORT™NeoFX™ agent was mixed with diluted miRNA by pipetting and 
incubated for another 10 minutes at room temperature to allow transfection complex 
to form. After final incubation, the transfection complex was add directly to 
pre-coated cell culture flasks or plates, followed by re-seeding the cells in culture 
medium as prepared above. The flaks or plates were gently tilted back and forth to 
evenly distribute transfection complex and cells, and incubated in 37°C and 5% 𝐂𝐎𝟐 
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incubator. In our preliminary studies, we observed the optimized concentration of 
miRNA precursors or inhibitors for transfection was 30nM. Culture medium was 
changed 24 hours post transfection, and cells were harvested 48 hours to 72 hours 
after transfection for further analysis. 
  
 T25 flask 6 well plate 24 well plate 
Total number of cells 6 × 105 3 × 105 4 × 104 
Table 1 Cell density used for miRNA reverse transfection 
 
2.3.2 miR-34a and Sirt-1 siRNA co-transient transfection 
Mouse ES cells were seeded on collagen coated T25 flasks in differentiation medium 
for 2-3 days before transfection. On the day of transfection, miR-34a mimics 
(MISSION® microRNA Mimic has-miR-34a, Sigma-Aldrich), SirT1 specific siRNA 
(Mission esiRNA targeting mouse SIRT-1, Sigma-Aldrich), or respective 
miRNA/siRNA negative controls (25nM each) were transfected into cells by using 
siPORTTMNeoFXTM agent in a similar method as described in 2.3.1. Transfected 
cells were cultured in 5µg/ml collagen coated flasks or plates for 48 to 72 hours in 
the SMC differentiation medium before harvest. 
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2.3.3 Transfection of plasmids into ES cells 
Related plasmids or respective control were transfection into cells by using Fugene-6 
(Roche) or Turbofect transfection agent (Thermo) according to the manufacturer’s 
instructions. Briefly, the ratio of transfection agent to DNA is 1:3 for Fugene-6 and 
1:2 for Turbofect. On the day of transfection, normal cell culture medium was 
replaced by 50% volume of antibiotics free medium with 5% FBS at least 1 hour 
prior to transfection. Transfection agent was first diluted with serum free Opti-MEM 
and incubate at room temperature for 5 minutes. After incubation the diluted 
transfection agent was mixed with plasmids by pipetting up and down several times 
and incubated at room temperature for 15 to 20 minutes. After incubation the 
transfection complex was drop-wise added to cell culture plates or flasks with 
antibiotics free cell culture medium contains 5% FBS and incubated in a 37°C and 5% 
CO2 incubator for 6 to 8 hours. Same volume of cell culture medium with 15% FBS 
was add to the cell/transfection mixtures to restore the level of FBS back to 10% and 
the cells were left in a 37°C and 5% CO2 incubator overnight. On the next day the 
old medium was replaced by normal cell culture medium and incubated at 37°C and 
5% CO2 till 48 to 72 hours post transfection for analysis.  
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2.4 miR-34a overexpressing ES cells 
2.4.1 Generation of miR-34a over-expression lentiviral particles 
Control and miR-34a over-expression lentiviral particles were produced by using 
control (pLL-3.7-GFP, Addgene, Plasmid 11795) and miR-34a 
(pLL3.7-GFP-miR-34a, Addgene, Plasmid 25791) plasmids DNA respectively. 293T 
cells were cultured in T75 flask at least 24 hours prior to transfection, and  then 
co-transfected with pLL3.7-GFP (control) or pLL3.7-GFP-miR-34a (miR-34a 
over-expression) and three packaging plasmids [pMDLg/pRRE (Addgene, 12251), 
pRsv-Rev (Addgene, 12253) and pMD2.G (Addgene, 12259)] by using Fugene-6 
transfection agent. On the next day the old medium was replaced by fresh complete 
medium. Supernatant containing the lentivirus was collected into 15 ml tubes 48 
hours post transfection and spun at 3,000 RPM for 5 minutes at room temperature. 
The supernatant was filtered with 0.45 µm filters, aliquoted and stored at -80 °C for 
future using. 
 
2.4.2 Lentiviral infection and cell sorting 
Mouse ES cells were seeded on T25 flaks 24 hours prior to infection and incubated 
in 37°C and 5% CO2 incubator. 1ml of respective lentiviral particles was added into 
culture medium with 10µg/ml polybrene (hexadimethrine bromide, H9268; 
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Sigma-Aldrich) and incubate at 37°C and 5% CO2 for 24 hours. Medium containing 
viral constructs was replaced with complete medium after 24 hours of incubation. 
Cells were cultured for further 2 to 3 days and GFP-positive cells were sorted out by 
using anti-GFP antibody and anti-FITC microbeads (Miltenyi Biotec Ltd.) according 
to the manufacturer’s instructions. In some cases, sorted GFP-positive cells were 
subjected to flow cytometry analyses to evaluate its cell purity.  GFP-positive ES 
cells were cultured in ES cell medium for 2 to 3 passages before using. 
 
2.4.3 SMC in vivo differentiation and immunofluorescent staining 
for sections  
SMC in vivo differentiation was conducted as described in our previous studies (Xiao 
et al., 2012, Huang et al., 2013). Briefly, control or miR-34a overexpression ES cells 
(1 × 106cells) were mixed with 50 µl of Matrigel (Becton Dickinson Labware) and 
PDGF-BB (100 ng/ml) at 4 °C and subcutaneously injected into C57BL/6J mice. 
After 10 to 13 days, mice were sacrificed and the implants (Matrigel plugs) were 
harvested. Half of each Matrigel plug was snapped frozen with liquid nitrogen and 
subjected to cryo-sectioned for detection of cell markers, and the rests were lysed for 
total RNA and protein extraction to examine related gene expression levels by 
Real-Time PCR and Western blot, respectively. All animal experiments were carried 
out according to protocols approved by the Institutional Committee for Use and Care 
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of Laboratory Animals. 
 
For immunofluorescent staining, sections were cut at 8 µm for optimum cutting 
temperature compound-embedded Matrigel implants, every 40 µm along the 
longitudinal axis of Matrigel plugs. The cut sections were numbered and given 
numbered sections (for instance, sections 5, 15, and 25) were picked up on 
Superfrost Microscope Slide (Thermo Scientific) subjected to immunohistological 
analysis with respective antibodies. Frozen sections were air-dried for at least 30 
minutes followed by fixed in cold acetone for 15 minutes. The sections were then 
washed with PBS and blocked with 5% BSA (Sigma-Aldrich) in PBS for 1 hour at 
room temperature in a humid chamber. After 1 hour the samples were incubated with 
primary antibodies against SM-MHC, GFP or IgG controls in blocking buffer in a 
cold room (4 °C) overnight. On the next day the samples were washed with PBS then 
incubated with appropriate FITC or TRITC conjugated secondary antibodies for 60 
minutes at room temperature. After incubation the samples were washed with PBS. 
Finally the samples were incubated with DAPI (1:1,000, Sigma-Aldrich) for 5 
minutes, washed with PBS then mounted with glycerol-PBS.  Images were assessed 
with Axioplan 2 imaging microscope with Plan-NEOFLUAR 20X, NA 0.5 objective 
lenses, AxioCam camera and Axiovision software (Carl Zeiss MicroImaging, Inc) at 
room temperature, and processed with Photoshop software (Adobe). The percentage 
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of GFP-labeled SM-MHC positive cells per field was counted by two trained 
independent investigators blinded to the treatment from random high power fields 
(200×) in each sections, 3 sections from each implant and four implants from each 
group. 
2.5 SIRT1 inhibitor and SIRT1 agonist treatment 
2.5.1 SIRT1 inhibitor treatment  
SIRT1 inhibitor (SIRT1 inhibitor III, EMD Millipore) were diluted in DMSO and 
stored in aliquots at – 20 °C. Control (pLL3.7-GFP) and miR-34a over-expressing 
( pLL3.7-GFP-miR-34a) were seeded on collagen coated T25 flasks in differentiation 
medium for 4 days to induce differentiation. On day 4, SIRT1 inhibitor (500 nm) or 
same volume of carrier vehicle (DMSO) were added into fresh differentiation 
medium and incubated at 37°C and 5% CO2 for 6 or 12 hours before harvest.  
 
2.5.2 SIRT1 agonist treatment 
Resveratrol (Sigma-Aldrich) were diluted in ethanol at 100mM and stored at -20°C. 
Mouse ES cells were seeded on collagen coated flasks or plates in differentiation 
medium to allow SMC differentiation before treatment. Day 2-3 differentiating ES 
cells were incubated with fresh medium containing resveratrol (5 or 10 µm) or same 
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volume of carrier vehicle (ethanol) for 24 to 28 hours before harvest. 
 
2.6 RNA extraction and analysis 
2.6.1 Extraction of total RNA from cells 
Before harvesting, cell scrappers were sterilized in 70% Ethanol for 10 minutes then 
rinsed in cold 1X PBS. Cell culture medium from flasks or plates was discarded and 
washed with 1 X PBS once. Cells were scrapped in cold PBS to minimum enzyme 
activity. Scrapped cells in cold PBS were collected in sterilized 1.5 ml tubes and 
centrifuged at 4°C, 6,000× g for 2 minutes. Supernatant was discarded and cell pellet 
were either proceed to RNA extraction or stored at - 80 °C. 
 
All RNA related work was performed in a sterile and RNase free manner. Working 
surface was cleaned by using 70% Ethanol. Pipette tips and tubes were autoclaved 
before use to minimum the risk of RNA degradation or contamination. Total RNA 
was extracted by using GenElute™ Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich) according to the manufacture instruction. 2-mercaptoethanol was 
added into Lysis Solution for that day’s use at a ratio of 1: 100 to fully inactivate 
RNase. For each tube of cell pellet (up to 5 x 105  cells), 250µl of Lysis 
Solution/2-mercaptoethanol mixture was added into the tube and vortexed till all 
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clumps disappear. Each sample was then transferred to a GenElute™ Filtration 
Column placed in a 2 ml collection tube, and centrifuged at room temperature, 
16,000 × g for 2 minutes. Filtration Column was discarded from collection tube, and 
250 µl 70% Ethanol was added to the collected supernatant then mixed well by 
pipetting up and down to precipitate the RNA. Up to 500 µl of lysate/ethanol mixture 
from each sample was transferred into a GenElute™ Binding Column placed in a 2 
ml receiving tube and centrifuged at 16,000 × g for 15 seconds. After discarding the 
flow-through, GenElute™ Binding Column was placed back into the receiving tube. 
500 µl of Wash Solution 1 was added to each column and spun at 16,000 × g for 15 
seconds. The binding Column was transferred to a new collection tube. 500 µl Wash 
Solution 2 was added to each tube and centrifuged at 16,000 × g for 15 seconds. 
After discarding flow-through sample was washed again with 500 µl Wash Solution 
2 and spun at 16,000 × g for 2 minutes. Wash Solution was removed from collection 
tube and samples were centrifuged again at 16,000 x g for 1 minute to fully remove 
ethanol. Binding column was transferred to a new RNase free collection tube. 50 µl 
of elution solution was added to each column and incubate for 1 minutes at room 
temperature. Samples were spun at 16,000 × g for 1 minute and RNA samples were 
placed on ice after centrifugation. The concentration of RNA samples was then 
measured with Nanodrop spectrophotometers and RNA samples were stored at – 
80 °C. 
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2.6.2 MicroRNA extraction  
Total RNAs includes small RNAs were isolated from cells by using 
     e  e  ®(Sigma-Aldrich) according to manufacturer’s instructions. Cells were 
scrapped from flasks in cold 1X PBS into RNase free tubes as described in 2.6.1.. 
1ml of      e  e  ®(Sigma-Aldrich) was added to each tube of cell pellet and 
mixed by pipetting up and down. For cells cultured in 6-well plates, 1ml of 
     e  e  ® was directly added to each well and the cell lysate was pipetted 
through a pipette tip several times to form a homogenous lysate, and transferred to 
RNase free tube. The samples were left at room temperature for 5 minutes to ensure 
complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform 
(Sigma-Aldrich) was added to each tube and shook vigorously for 15 seconds. The 
mixture was left at room temperature for 5 minutes and then centrifuged at 12,000 × 
g for 15 minutes at 4 °C. Only colorless upper aqueous phase was transferred to a 
new RNase free tube, and 0.5 ml of 2-propanol was added to each tube. Samples 
were left at room temperature for 10 minutes then centrifuged at 12,000 × g for 10 
minutes at 4 °C. The supernatant was removed and RNA pellet was washed by using 
1 ml of 75% ethanol and vortexed. The samples were centrifuged at 7,500 × g for 5 
minutes at 4 °C and the supernatant was discarded. RNA pellet was air dried for 10 
minutes. 30 µl of RNase free water was added to each RNA pellet and mixed by 
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pipetting. The RNA samples were then incubated at 55 °C for 10 minutes to facilitate 
dissolution and placed on ice, while the concentration of RNA samples was measured 
by Nanodrop. The RNA samples were stored at – 80 °C 
 
2.6.3 Reverse Transcription-Polymerase Chain Reaction 
Prior to Reverse Transcription-Polymerase Chain Reaction (RT-PCR) the RNA 
samples (excluding small RNAs) were mixed by vortex. 1 µg of RNA was diluted 
with RNase-free water to make a total volume of 9 µl and mixed with 1 µl of 
Random Primer (50ng/µl, Promega). The samples were placed on a Thermal Cycler 
(Techne, Staffordshire, UK) , which ran a program of 70 °C for 5 minutes followed 
by cooling down to 4 °C to destabilize RNA secondary structures and enhance 
primer binding. The master mix for RT-PCR was prepared while the program was 
running. The volume of master mix for each reaction is 15 µl, which consists of 4.5 
µl of RNase-free water, 5 µl of 5X Reaction buffer (Promega), 3 µl of 25mM 
magnesium chloride (M Cl2), 1 µl of 25mM 2'-deoxynucleoside 5'-triphosphate 
(DNTPS; Invitrogen), 1 µl of Improm-II reverse transcriptase and 0.5 µl of RNasin 
Plus RNase inhibitor (Promega). The master mix was combined with samples and 
placed into the block of Thermal Cycler, which ran a program of 25 °C for 5 minutes 
for annealing followed by an extension at 42 °C for 90 minutes. The reaction was 
then stopped by enzyme denaturation at 70 °C for 15 minutes, then cooled down and 
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hold at 4°C. The final concentration of each synthesized complementary 
Deoxyribonucleic acid (cDNA) samples was diluted to 5ng/µl and stored at -20 °C. 
 
NCode™ VILO™ miRNA cDNA Synthesis Kit (Invitrogen) was used to synthesize 
ploy(A) tails of all the microRNA, and then synthesizing cDNA from the tailed 
population in a single reaction. Each reaction consists of 500 ng RNAs, 2 µl of 5× 
Reaction Mix, 1 µl of 10× SuperScript® and topped up to 10 µl with RNase-Free 
water. The samples were vortexed to mix and centrifuged briefly before placing in a 
Thermal Cycler, which ran a program set at 37 °C for 60 minutes then raised to 
95 °C for 5 minutes to terminate the reaction, and held at 4 °C at the end. The cDNA 
samples were diluted to 5ng/ µl and stored at -20 °C.  
 
In some experiments, negative control or mock reverse transcription containing all 
the RT reagents, except the reverse transcriptase (for nornmal RNA) or 10× 
SuperScript® (for miRNA), respectively, were conducted to distinguish genmic 
DNA contamination. 
 
2.6.4 Real-Time Polymerase Chain Reaction 
The working area was cleaned with 70% Ethanol and only sterilized pipette tips and 
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tubes were used when preparing Real-Time Polymerase Chain Reaction 
(RealTime-PCR) samples. cDNA samples were thawed from -20 °C and placed on 
ice. The master mix for one reaction of RT-PCR for mRNA contained 5 µl of KAPA 
SYBR FAST qPCR Master Mix (Kapa Biosystems). 0.75 µl of 2 µm forward primer, 
0.75 µl of 2um reverse primer and 1.5 µl of RNase-free water. For microRNA 
samples, the master mix consists of 5 µl of NCode™ EXPRESS SYBR® 
Gree E TM qPCR SuperMix, 0.75 µl of 2 µM miRNA specific forward primer, 
0.75 µl of 2 µM miRNA Universal Primer (Invitrogen) and 1.5 µl of RNase-free 
water. The master mix was vortexed then aliquoted at 8 µl for each reaction in a well 
of a MicroAmp® Optical 384 wells plate. 2 µl of 5 ng/µl cDNA sample was added 
into its respective well and each sample was carried out in duplicates. The 384 wells 
plate was sealed with MicroAmp® PCR film, vortexed briefly and centrifuged at 
1,200 × g for 1 minute. ABI HT 7900 was used to run the PCR reaction, which has a 
program of 50°C for 2minutes, 95°C for 10 minutes, 40 cycles of 95 °C for 15 
seconds and 60°C for 1 minute. Once the reaction has completed, the result was 
analyzed with SDS 2.3 software (Applied Biosystems). The Pfaffl’s method (Pfaffl, 
2001) was applied to determine the different expression levels of a gene of interest 
between a control and a treated sample. Briefly, the amount of the target gene is 
normalized towards an internal control housekeeping gene (in this case the 18S gene 
or U6 RNA) in both the control and the treated sample and it is expressed by the 
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formula: 2
-δδCt, where δδCt = δ Ct,T – δCt,C, with δ Ct,T as the difference between 
the Ct of the gene of interested and the housekeeping gene in the treated sample and 
δCt,C as difference between the Ct of the gene of interested and the housekeeping 
gene in the control sample.    
 
2.7 Protein extraction and analysis. 
2.7.1 Chemicals and buffer 
Name Components 
RIPA buffer 
 
Tris-HCl: 50mM, pH 7.4. 
NP-40:1% 
Na-deoxycholate: 0.25% 
NaCl: 150mM 
5× SDS loading buffer Tris-Cl (0.25 M, pH 6.8) 
SDS (sodium dodecyl sulfate; 10%) 
Glycerol (50%) 
Bromophenol blue (0.25%) 
DTT (dithiothreitol; 0.5 M) 
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10× Tris Glycine buffer, pH8.4 
1 Liter 
Tris base: 30.3g 
Glycine:144.1g 
Distilled water to 1 Liter 
1× Running buffer 
1 Liter 
10 × Tris Glycine buffer: 100 ml 
10% SDS: 10ml 
Distilled water to 1 Liter 
 
1 × Transfer buffer 
1 Liter 
10 × Tris Glycine buffer: 100 ml 
Methanol : 200ml 
Distilled water to 1 Liter 
 
10 × TBS buffer 
1 Liter 
Tris HCl: 24g 
Tris Base:5.6g 
NaCl: 88g 
Distilled water to 1 Liter 
1 × TBS-T 10 × TBS: 100ml 
Tween® 20:500µl 
Distilled water to 1 Liter 
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Table 2 Recipes of buffer used in protein analysis 
All chemicals were from Sigma Aldrich unless specifically indicated. 
 
2.7.2 Protein extraction from cells 
Cell pellets were collected by using cell scrappers in cold 1× PBS. After removing of 
PBS, the cell pellets were either stored at - 80°C or proceed to protein extraction. 
Each cell pellet was mixed with 100 µl of Lysis buffer [RIPA buffer containing 
Protease Inhibitor Cocktail (Sigma-Aldrich)] and sonicated at 4°C to disrupt cell 
membrane and release protein contents. The lysates were left on ice for 1 hour and 
vortexed every 15 minutes to allow fully lysis of cells. After incubation the samples 
were centrifuged at 16,000 × g for 10 minutes at 4 °C. Up to 100 µl of supernatant 
from each sample was transferred into new pre-cooled 0.5 ml tubes and placed on ice. 
The concentrations of proteins were measured by using BIORAD Protean assay 
solution (BIO-RAD, Herts, UK). The assay solution was first diluted at 1:5 by using 
Distilled water. 2 µl of each protein sample was added to 998 µl of diluted BIORAD 
Protean assay solution, vortexed and incubated for 10 minutes at room temperature. 
Protein concentrations were measured by using a spectrophotometer (SmartSpec™ 
3000; BIO-RAD). Lysis buffer and warmed 5× sodium dodecyl sulfate (SDS) protein 
loading buffer were then added into each sample to adjust the concentration. The 
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protein samples were placed into a heat block and denatured at 95°C for 10 minutes, 
followed by vortexing and then centrifuged briefly. After cooled down at room 
temperature for 3 minutes, the samples were stored at – 80 °C. 
 
2.7.3 Western blot and immunodetection 
Electrophoresis was carried out with Mini-PROTEAN® Tetra Cell system 
(BIO-RAD, UK) and the protein was separated by SDS PAGE with 6-10% 
Tris-clycine gel. The gels were prepared on the day of experiment, and 4ml of 10% 
separating gel consists of 1.6ml double-distilled water, 1.635ml of 30% Acrylamide 
(National diagnostics, USA), 1ml of 1.5M Tris buffer pH 8.8, 40µl of 10% SDS, 
40µl of 10% APS and 4 µl of TEMED, while 2.5 ml of 6% Stacking gel consists of 
1.3 ml of double-distilled water, 0.5 ml of 30% Acrylamide,0.625 ml of 0.5M Tris 
buffer pH 6.8, 25 µl of 10% SDS, 25µl of 10% APS and 2.5 µl of TEMED. 4ml of 
separating gel was first added into the glass casting chamber followed by 1ml of 
butanol (Sigma-Aldrich) to flatten the gel. After 10 minutes, the butanol was 
discarded from the chamber and 2.5 ml of stacking gel was added on top of the 
separating gel. Plastic comb was placed into the gel to create 10 wells in each gel, 
and incubated at room temperature for 10 minutes. 40 µg of each protein sample was 
added into the wells of the gel, with 15 µl of ColorPlus Prestained Protein Ladder 
(New ENGLAND BioLabs®inc) loaded in the first well of the gel. The gels were run 
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at a fix voltage of 160 V for 1 hour 15 minutes in 1× running buffer at room 
temperature. Polyvinylidene difluoride (PVDF) membranes (GE Healthcare) were 
first activated in methanol (Sigma-Aldrich) then soaked in 1× transferring buffer. 
Blotting sponges were washed with distilled water then soaked in 1 × transfer buffer 
with filter papers. The gels were transferred into blotting cassettes with pre-wetted 
membranes, blotting sponges and filter papers. The assembly was carried out in 1× 
transfer buffer and air bubbles were removed by rolling over the surface with a roller. 
The blotting cassettes were inserted into a Mini Trans-Blot Central Core (BIORAD) 
and placed back to the running cell filled with cold 1× transfer buffer and a cooling 
pack. The proteins were electro-transferred to membranes for 2 hours 30 minutes at 
60 V. 
 
The membranes were removed from blotting cassettes after transfer and blocked in 5% 
silk milk in TBST buffer on a 2-D rocker, with the protein facing upwards for 1 hour 
at room temperature. The membranes were then incubated with primary antibodies in 
5% silk milk in TBST on a slow roller at 4 °C overnight. 
 
The membranes were taken out from primary antibodies and washed with 1× TBST 3 
times for 10 minutes each wash on a shaker, and then incubated with horseradish 
peroxidase conjugated secondary antibodies in 5% milk TBST for 1 hour at room 
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temperature. After incubation, the membranes were washed again with 1× TBST 3 
times for 10 minutes each wash. Finally the membranes were incubated with 
ECL-PLUS reagent (Amersham Biosciences, Stockholm, Sweden) for 3 minutes 
at room temperature. After removing the excess ECL reagent, the membranes were 
wrapped in a clean plastic film and placed in an autoradiographic cassette. 
Membranes were exposed to Hyperfilm ECL (GE Healthcare) for normally 10 
seconds to 2 minutes (depending on signal strength) in a dark room, and films were 
developed with an X-Ray film processor (SRX-101A. Konica Minolta, USA).  
 
 
2.8 Transient transfection and luciferase assay 
2.8.1 SirT1 3’UTR reporter cloning and miR-34a binding sites 
mutation 
Reporter vector harboring sequences of murine SirT1 was created using cDNA from 
differentiating ES cells. The 3’-flanking untranslation region (2306bp/3636bp) of 
murine SirT1 gene (NM_019812.2) containing two miR-34a binding sites was 
amplified by PCR with primers shown in appendix, and cloned into 
pmiR-reporter-basic vector (Ambion, Applied Biosystem) at Mlu I and Sac I sites, 
designated as pmiR-Luc-SirT1-WT. miR-34a binding sites 1,2 mutation alone or 
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dual mutation were introduced into pmiR-Luc-SirT1-WT by using QuickCh   eTM 
site-directed mutagenesis kit (Agilent Technologies) according to manufacturer’s 
instructions. They were designated as pmiR-Luc-SirT1- BS1mu , 
pmiR-Luc-SirT1-BS2muand pmiR-Luc-SirT1-BS1/2mu  mutants, respectively. An 
artificial miR-34a binding site from SirT1 3’UTR was introduced into pmiR-Luc by 
using PCR based on QuickCh   eTM  site-directed mutagenesis, designated as 
pmiR-Luc-miR-34a binding site. All vectors were verified by DNA sequencing from 
Genome Centre, WHRI. 
 
2.8.2 Amplification and extract of plasmid 
Transformation was used to amplify DNA. Tubes and pipette tips were sterilized 
before use and working area were sterilized with 70% Ethanol. Competent cells 
(JM109) were taken out from -80°C and thaw on ice. The cells were aliquoted into 
cold 0.5ml tubes (20µl/tube) and mixed with 1 µl of plasmids/DNA or negative 
control (DDH2O). The mixture was incubated on ice for 30 minutes then placed into 
a heat block at 42°C for 60 to 70 seconds, followed by incubating on ice for 1 minute. 
500µl of LB medium was added into each tube and the samples were incubated at 
180 RPM, 37 °C in a floor shaker for 1 hour. The mixture was then centrifuged at 
5,000 x g for 5 minutes, and 400 to 450 µl of supernatant was discarded. The cells 
were re-suspended in the remaining supernatant and added into LB-plates drop-wise 
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with appropriate antibiotics by pipetting. The LB-plates were lightly smashed with 
sterilized “L” rode and placed into a 37 °C incubator to culture overnight. On the 
next day, single clone was taken into 14ml tubes containing 5ml LB with antibiotics 
and placed into a floor shaker at 200 RPM, 37 °C to culture for 12 to 18 hours. The 
samples were centrifuged at 4,000 × g for 10 minutes and supernatant was discarded 
to collect the cell pellets. Plasmids were extracted using GenElute™ Plasmid 
Miniprep Kit (Sigma-Aldrich) according to manufacturer’s instruction. The 
concentrations of plasmid were measured using NanoDrop and plasmids were stored 
at – 20 °C.  
    
2.8.3 Luciferase activity assay 
Undifferentiated, day 2-4 differentiating ES cells or terminally differentiated (Day 8) 
SMCs (40,000 cells per well of 24-well plate) were co-transfected with individual 
reporter gene (pmiR-Luc-SirT1-WT, pmiR-Luc-SirT1- BS1mu , pmiR- 
Luc-SirT1-BS2mu, pmiR-Luc-SirT1-BS1/2mu, pmiR-Luc-ZEB1 (Luo et al., 2013) , 
pmiR-Luc-MECP2 or pmiR-Luc-miR-34a binding site, 180 ng/well), pRenilla (20 
ng/well), and mir-34a precursor and negative control miRNA precursor (30nM) by 
using siPORTTMNeoFXTM  according to the manufacturer’s instructions. The cells 
were cultured on gelatin or collagen coated 24-well plate for 48 hours after 
transfection, with 1 medium change at 24 hours post transfection.  
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After 48 hours of incubation, culture medium was removed from wells and the cells 
were washed with 1× PBS once. After removing of PBS, 100µl of Reporter Lysis 
Buffer (Promega) was added into each well and the cell culture plate was placed on a 
2-D rocker at 200RPM for 20 minutes at room temperature. The cell culture plate 
with Lysis buffer was placed into a -80°C freezer for at least 2 hours and thaw on a 
2-D rocker again at 200 RPM for 20 minutes at room temperature. The lysates from 
each well were transferred into 1.5ml tubes and centrifuged at 16,000 x g at 4 °C for 
5minutes. 15 µl of supernatant from each samples were mixed with Luciferase or 
Renilla substrates (Promega) to detect the activities with a Single-Tube Luminometer 
(Turner BioSystem, Sunnyvale, CA, USA). Relative Luciferase unit (RLU) was 
defined as the ratio of Luciferase versus Renilla activities with that of the control set 
as 1.0. 
 
For Gene promoter luciferase activity assays, day 2 – day 4 differentiating cells 
cultured in 24-well plate (40,000 cells) were co-transfected with respective gene 
promoter reporter (pGL-3-Luc-gene, 150 ng/well), pshuttle2-LacZ (200 ng/well) or 
control plasmid (pcDNA 3.1, 200 ng/well), or SirT1 overexpression plasmids 
(pcDNA3.1-SirT1, 200 ng/well) using Fugene-6 (Roche) or Turbofect transfection 
agent (Thermo) according to the manufacturer’s instructions. The cells were cultured 
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in differentiation medium for 48 to 72 hours after transfection with 1 medium change 
at 24 hours post transfection. The gene promoter reporters used in this study were 
generated in our previous studies (Huang et al., 2013, Margariti et al., 2009), 
including pGL3-Luc-SmαA, pGL3-Luc-SM22α, pGL3-Luc-SMαA-SRFmu,   
pGL3-Luc-SM22α-SRFmu, pGL3-Luc-SRF pGL3-Luc-MEF2c and 
pGL3-Luc-Myocardin. pShuttle2-LacZ (0.20 μg/2.5 × 104 cells) was included in all 
transfection assays as internal control. Luciferase activity was detected as described 
above and β-galactosidase activity was measured using a standard protocol. Relative 
Luciferase Unit (RLU) was defined as the ratio of Luciferase versus β-galactosidase 
activities with that of the control set as 1.0. 
 
 
2.9 Immunoprecipitation 
2.9.1 Chromatin immunoprecipitation (ChIP) assay 
Differentiating ES cells were transfected with control (pcDNA3.1) or SirT1 
over-expression (pcDNA3.1-SirT1) plasmids using Turbofect transfection agent 
(Thermo) in T75 flasks and cultured for 48 hours after transfection, with one medium 
change at 24 hours. 1% (v/v) of formaldehyde was added into cell culture medium in 
T75 flasks, incubated at room temperature for 10 minutes and then quenched with 
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glycine. The medium was removed and cells were harvested, resuspended in SDS 
lysis buffer and sonicated. The sheared samples were diluted into 1ml of 
immunoprecipitation buffer containing 25mM Tris-HCL, pH 7.2, 0.1% NP-40, 150 
mM NaCl. 1mM EDTA, and immunoprecipitation were carried out with antibodies 
(2µg/immunoprecipitation) raised against SirT1 (rabbit, H-300, sc-15404, Santa 
Cruz), SRF (rabbit, G-20, sc-335, Santa Cruz) or H3K9me3 (mouse, 05-1250, 
Millipore) together with single-strand salmon sperm DNA saturated with 
protein-G-Sepharose beads. Equal amount of normal rabbit lgG or mouse lgG was 
used as control. The samples were placed on a roller and incubated at 4 °C overnight. 
The immunoprecipitations were eluted from the beads using 100 µl elution buffer 
(50mM N HCO3, 1% SDS). 200 µl of proteinase K solution was added to each 
samples and incubated in a heat block at 60 °C overnight. Immunoprecipitaed DNA 
was extracted, purified and then used to amplify target DNA sequences by Real-Time 
PCR with specific primers. Relative DNA level (or promoter DNA enrichment) was 
defined as the ratio of immunoprecipitated promoter DNA level to its input level with 
that of the control sample (pcDNA3.1) set as 1.0. PCR amplification of the adjacent 
promoter regions or regions lacking of SRF binding sites (without CArG region) 
were included as additional control for specific promoter DNA enrichment. The 
respective target promoter DNA was almost undetectable or with much higher CT 
value in normal IgG control samples. The data was obtained from four independent 
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experiments.   
 
2.9.2 RNA immunoprecipitation (RNA-IP) assays 
Undifferentiated ES cells or day 4 to day 6 differentiating SMCs were treated with 1% 
formaldehyde at room temperature for 10 minutes and then quenched with glycine at 
room temperature. Cells were harvested, resuspended in Lysis buffer containing 
RNase inhibitor, and sonicated in a sonicate machine (Spishaer™ Probe Sonicator). 
The sheared samples were diluted into 1ml immunoprecipitation buffer and 
incubated with 5µg of Ago 2 antibody (Fisher Scientific, MA5-14861) or equal 
amount of rabbit lgG together with protein-G Dynabeads® saturated with 
single-strand samon sperm DNA at 4 °C overnight. The immunoprecipiates were 
saturated with DNAse and eluted from the beads using 100 µl of elution buffer. The 
immunoprecipitaed RNA was extracted, purified and then used to synthesize cDNA 
by using NCode™ VILO™ miRNA cDNA Synthesis Kit according to 
manufacturer’s instructions. The cDNA samples were used to amplify target RNA 
sequences by Real-Time PCR using specific primers. The respective target 
RNA/miRNA levels were almost undetectable or with much higher CT value in 
normal IgG control samples. RNA enrichment with specific antibody was calculated 
using percent input method with that of the IgG control set as 1.0. The relative level 
of RNA enrichment was defined as the ratio of RNA enrichments in the treatment 
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groups (differentiated SMCs) to the control groups (undifferentiated ES cells) with 
that of the control samples set as 1.0. PCR amplification of the murine SirT1 coding 
region was included as additional control for specific RNA enrichment. 
 
2.10 Flow cytometry, cell cycle, proliferation, and apoptosis 
analysis. 
2.10.1 Flow cytometry analysis 
Flow cytometry analysis were performed either using direct or indirect method 
depending on the antibodies of interest. Differentiated ES cells were dissociated into 
single cells by trypsion-EDTA, counted in culture medium and centrifuged at 1,000 
×g for 5 minutes. The cell pellets were collected and washed with cold 1× PBS 
containing 10% FBS. 1 ml of cold 4% Paraformaldehyde (PFA, for per 1 × 105 to 5 
× 105 cells) was mixed with cells and incubated on ice for 15 minutes. The mixture 
was then centrifuged and supernatant was removed. For intracellular markers 
detection, 1 ml of cold permeabillization buffer (PBS-0.1% Tritron X-100, per 1 × 
105 to 5 × 105 cells) was added to the cell pellet, votexed and incubated on ice for 
5 to 10 minutes. Permeabillization buffer was removed by centrifuged and the cell 
pellets were resuspended in 10 % FBS in PBS to adjust the cell concentration to 1 × 
107 per ml, and incubated on ice for 20 minutes to block non-specific antibody 
74 
 
binding. 100 µl of single cell suspension was aliquoted into individual tubes and 
stained with either antibodies against GFP, SMαA, SM-MHC, or Isotype IgG 
negative controls. The mixture was vortexed and incubated for 1 hour at room 
temperature in a dark box. After 1 hour, each tube was washed with 1 ml of cold PBS 
and supernatant was removed by centrifugation and pipetting. Appropriate amount of 
secondary antibodies (1:50 to 1:100) was diluted with PBS containing 10% FBS and 
mixed with the respective cell pellets. The mixture was incubated at room 
temperature in a dark box for 30 minutes and then washed twice with cold PBS. 
After removing of PBS, the cell pellets were re-suspended in 400 µl of 1% PFA and 
analyzed using a FACSCalibur sorting system (Becton Dickinson). 
 
2.10.2 Cell cycle and apoptosis analysis 
Mouse ES cells at the indicated time points or with different treatments were 
dissociated into single cells using trypsin-EDTA and collected in cell pellets. The cell 
pellets were washed with PBS twice and then re-suspended in 300 µl of PBS. 3 ml of 
70% ethanol was added drop-wise into the cell pellets and incubated at 4 °C for at 
least 30 minutes. Fix cells were then washed twice with PBS, and incubated in PBS 
containing 0.01 % Triton X-100, 40 µg/ml RNase and 50 µg/ml propidium iodide 
(All from Sigma-Aldrich) for 45 minutes at 37 °C. The samples were washed again 
with PBS the re-suspended in PBS and cell cycle distribution was analyzed using a 
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FACSCalibur sorting system (Becton Dickinson). 
 
For apoptosis analysis, day 2 to day 3 differentiating ES cells were transfected with 
miR-34a precursor or negative control and cultured in differentiation medium for 48 
hours after transfection. The cell pellets were collected and subjected to apoptosis 
analysis using Annexin V-FITC/P1 kit (BMS306F1; Bender MedSystem) according 
to manufacturer’s instructions. The binding buffer was first diluted at 1:4 in distilled 
water. The cell pellets were washed with PBS and resuspended in the diluted binding 
buffer to adjust the cell density to 2 ~ 5 × 10 105 per ml. 195 µl of cell suspension 
was mixed with 5 µl of Annexin V-FITC and incubated for 10 minutes at room 
temperature. After incubation the samples were washed with PBS once, centrifuged 
and re-suspended in 190 µl of diluted binding buffer. 10 µl of 20 µg/ml Propidium 
iodide stock solution was added into each sample and cell apoptosis was analyzed 
with FACSCalibur sorting system.    
 
2.10.3 BrdU incorporation 
Cell proliferation was evaluated using 5-bromo-2'-deoxyuridine (BrdU) Labeling and 
Detection Kit III (Roche) according to the manufacturer’s instructions. Day 2 to day 
3 differentiating ES cells were transfected with miR-34a precursor or negative 
control and seeded in gelatin coated 96-well plates (5 × 103cells per well) for 18 
76 
 
hours. Cells were then incubated with fresh differentiation medium containing 10 
µM BrdU for 12 hours. After removal of culture medium, the cells were washed with 
wash medium containing 10% FBS and then fixed with 200 µl of precooled fixative 
for 30 minutes at – 20 °C. The fixed cells were washed with 10% FBS wash medium, 
and cellular DNA was digested with nuclease by  incubating with 100 µl of 
nucleases working solution per well for 30 minutes at 37 °C. The samples were 
washed with washing buffer containing 10 % FBS and labeled with 
peroxidase-conjugated anti BrdU antibody (100 µl/well) for 30 minutes at 37 °C, 
followed by washing 3 times with wash solution II and then incubated withy 
peroxidase substrate (100 µl/well) at room temperature until positive samples 
showed a green color. The absorbance of the samples was measured by a microplate 
reader at 450nm with a reference wave-length at approx. 490 nm. 
 
2.11 Materials 
Antibodies against SirT1 (rabbit, H-300, sc15404), SRF (rabbit, G-20,sc-335) and 
MEF2c (goat, sc-13268) were from Santa Cruz Biotech, USA. Antibody against 
Smooth Muscle Mayosin Heavy Chain (SM-MHC) was from AbD Serotec (Rabbit, 
AHP1117). Antibodies against SM22α (Rabbit, AB14106) and calponin (rabbit, 
Ab46794) were from Abcam, UK. Antibodies against α-tubulin (mouse), SMαA 
(Clone 1A4, A5228) GAPDH (mouse) and GFP (G6539) were from Sigma Aldrich. 
77 
 
Antibody against H3K9me3 (mouse, 05-1250) was from Millipore. All secondary 
antibodies were from Dako, Denmark. Random siRNA control (MISSION® esiRNA, 
Negative Control) was from Sigma Aldrich. Other materials used in this study were 
from Sigma Aldrich unless specifically indicated. 
 
Primers for PCR related work and gene cloning were listed in Appendix. 
 
2.12 Statistical analysis 
Data were presented as mean ± standard error of the mean (SEM) and analyzed using 
a two- tailed student’s t-test for two group comparison or one-way ANOVA followed 
by Turkey’s HSD multiple comparison post-hoc test for comparing different groups. 
P value less than 0.05 were considered statistically significant. 
 
 
 
 
 
 
  
78 
 
CHAPTER 3 SMC differentiation induced 
by collagen  
 
Pluripotent mouse ES cells can differentiate into different types of cells, including 
vascular SMCs. It has been reported that one of extracellular matrix (ECM) proteins, 
collagen type IV, promotes SMC differentiation by activating several signal 
pathways (Huang et al., 2013, Pepe et al., 2010, Xiao et al., 2012, Xiao et al., 2011, 
Xiao et al., 2007). Interestingly, in these studies another ECM protein, type I 
collagen has also been suggested to play a similar role in SMC differentiation. To 
further confirm such a possibility, mouse ES cells were cultured in collagen type I 
coated T25 flasks and culture in SMC differentiation medium (DM) in the absence of 
LIF for 2 to 8 days to allow for SMC differentiation. A set of SMC markers, as well 
as SMC transcription factors and undifferentiated ESC markers were analyzed using 
real-time PCR and western blot, respectively. Taken together, the data demonstrated 
an increase expression of all the SMC specific genes examined in this study and 
several transcription factors over 8 days of differentiation, mostly reaching maximum 
level at day 6, while the gene expression levels of several undifferentiated 
ESC-specific transcription factors were significantly decreased from day 4, further 
validating the collagen-based SMC differentiation model.   
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3.1 SMC specific genes were up-regulated during ES cell 
differentiation 
Undifferentiated ES cells were cultured in collagen type I coated T25 flaks and 
cultured in differentiation medium in the absence of LIF. Cells were harvested at the 
indicated time points (day 0 to day 8). Total RNA was extracted and subjected to 
real-time PCR analysis. mRNA level of SMC specific genes, including SMαA, 
SM-MHC, Calponin and SM22α was significantly up-regulated from day 4 of 
differentiation as compared with that of day 0 (undifferentiated ES cells) and reached 
maximum level at day 6 (Figure 6). In contrast, expression level of undifferentiated 
markers including OCT3/4, Nanog and KLF4 was significantly decreased from day 2 
as compared with that of day 0 (Figure 7). 
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Figure 6  SMC specific gene expression over a period of 8 days 
Undifferentiated ES cells were cultured on collagen type I coated flasks and cultured 
for 2, 4, 6 and 8 days. Day 0 represent undifferentiated ES cells. Cells were harvested 
at indicated time points to extracted total RNA and subjected to real-time PCR with 
specific primer for SMαA, SM22α, calponin and SM-MHC. Data represent mean ± 
SEM of three independent experiments (n=3). mRNA level was normalized to 18s 
and presented relative to day 0 expression. Significant difference from control (day 
0), *P<0.05. 
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Figure 7 Stem cell specific transcription factors were silenced during SMC 
differentiation 
Same total RNA samples were harvested as described in Figure 1 and subjected to 
real-time PCR with specific primer for OCT3/4, Nanog and KLF4. Data represent 
mean ± SEM of three independent experiments (n=3). mRNA level was normalized 
to 18s and presented relative to day 0 expression. Significant difference from control 
(day 0),*P<0.05. 
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3.2 SMC transcription factors gene expressions were 
activated during SMC differentiation. 
SRF, Myocardin and MEF2C play an important role in SMC differentiation from ES 
cells. To establish the expression profiles of these SMC transcription factors in the 
SMC differentiation method, undifferentiated ES cells were induced to differentiate 
into SMCs as described above and cells were harvested at indicated time points. 
Total RNA was extracted and subjected to Real-Time PCR analysis. The results 
suggest that mRNA level of SRF and MEF2C significant increased from day 4, and 
reached maximum level at day 6 (Figure 8A and B), while mRNA level of myocardin 
increased at day 6 and reached maximum value at day 8 ( Figure 8C), as compared 
with mRNA level of respective SMC transcriptional factors from undifferentiated ES 
cells.  
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Figure 8 Expression of SMC transcription factors gene over 8 days of SMC 
differentiation 
Same total RNA samples were harvested as described in Figure 1 and subjected to 
real-time PCR with specific primers for SRF (A) Myocardin (B) and MEF2C (C). 
Data present mean ± SEM of 6 independent experiments. mRNA level was 
normalized to 18s and presented relative to day 0 expression. Significant difference 
from control (day 0),*P<0.05. 
 
 
 
 
 
 
84 
 
3.3 Western blot analysis of SMC specific marker 
expression in differentiating ES cells. 
Western blot was carried out to determine SMC specific gene expression product at 
indicated time points during SMC differentiation. Strong protein expressions of both 
SMαA and calponin was detected from day 6, while undifferentiated ES cells (day 0) 
did not express any SMC specific markers (Figure 9).  
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Figure 9 Western blot analysis of ES cells differentiation over 8 days. 
Undifferentiated ES cells were seeded on collagen coated flasks and cultured for 2, 4, 
6 and 8 days. Day 0 represented undifferentiated ES cells. The samples were detected 
by western blot analysis with antibodies against SMαA (Top) and calponin (Middle), 
respectively. α-tubulin was used as housekeeping protein (Bottom). The data 
presented here is representative of 3 independent experiments. 
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Chapter 4 Function role of miR-34a in 
SMC differentiation from ES cells 
 
Data from chapter 3, as well as other studies (Huang et al., 2013, Pepe et al., 2010, 
Xiao et al., 2012, Xiao et al., 2011, Xiao et al., 2007) suggested that collagen based 
stem cell differentiation model is a simple but efficient SMC differentiation model, 
which provides a useful platform to investigate the potential role of individual 
miRNA during SMC differentiation.  
  
4.1 Functional involvements of miR-34a in SMC 
differentiation in vitro and in vivo 
4.1.1 Screening potential miRNA during ES cells differentiation 
towards SMCs  
In order to identify potential miRNA candidates for SMC differentiation from ES 
cells, total RNA including small RNA from undifferentiated ES cells and 
differentiated ES cells over 4 days or 8 days were harvested and subjected to 
microRNA microarrays analysis (Miltenyi Biotec GmbH, Germany). Data from 
microarrays revealed that except miR-294, all other five members of miR-290 family, 
which were reported to be mouse ES cells specific miRNA cluster (Houbaviy et al., 
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2003), were down-regulated especially at day 8 of differentiation, further confirming 
cell differentiation (Table 3)SMC differentiation related miRNAs such as miR-143, 
miR-145 and miR-133 were increased in the SMC differentiation model, while 
miR-21 which involved in SMC proliferation was undetected at early stage of 
differentiation (day 4) but significantly increased at late stage (day 8), indicating that 
some miRNAs (eg. miR-143/145) may initiate SMC differentiation whereas others 
(eg. miR-21) may play important roles in the late stage of SMC differentiation where 
differentiated SMC proliferation is required to complete the SMC differentiation 
process. No significant changes were observed for other cell lineages specific 
miRNAs, such as miR-146 for T lymphocyte, miR-107 for monocytes, miR-203 for 
epidermal cell, miR-206 for myogenic cells, miR-124 for neural cells and miR-126 
for endothelial cells (Table 3). Taken together, these findings confirm the specificity 
of SMC differentiation. More important, the data suggested that miR-34a, a reported 
cell cycle mediator (He et al., 2007), was up-regulated to a greater magnitude over 8 
days of differentiation than some best known SMC differentiation related miRNAs 
miR-143 and miR-145. Expression level of miR-34a during SMC differentiation was 
further validated using real-time PCR analysis, and the result showed that miR-34a 
expression was significantly increased during SMC differentiation (Figure 10), 
indicating that miR-34a may be involved in the SMC differentiation system. 
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Name 
 
 
Fluorescence signal  
Reported functions 
 
 
Reference  
Day4/day0 
 
Day8/day0 
miR-290-5P 0.775761 0.286816 ES cell specific Houbaviy et al(2003) 
miR-291a-5P 0.925415 0.271932 ES cell specific Houbaviy et al(2003) 
miR-292-3P 1.427017 0.468515 ES cell specific Houbaviy et al(2003) 
miR-293 1.18702 0.411204 ES cell specific Houbaviy et al(2003) 
miR-294 1.146818 1.367687 ES cell specific Houbaviy et al(2003) 
miR-295 1.062308 0.265621 ES cell specific Houbaviy et al(2003) 
miR-143 1.470071 1.237568 SMC differentiation Cordes et al(2009) 
miR-145 2.113956 1.460188 SMC differentiation Cordes et al(2009) 
miR-21 UD 9.848351 SMC proliferation Ji et al(2007) 
miR-22 2.20227 11.205712 Tumour suppressor Xiong et al(2010) 
miR-24 0.987122 3.597099 
Heart contraction and 
myoblast differentiation 
Li et al (2013b), Sun et 
al(2008) 
miR-214 3.451106 2.024559 
Muscle cell specification and 
myogenesis 
Flynt et al(2007), Liu et 
al(2010) 
miR-146a 1.225387 UD T lymphopoiesis Georgantas et al(2007) 
miR-16 0.668986 1.187912 Universal expression  Landgraf et al (2007) 
miR-107 0.754878 0.861935 Monocytopoiesis Georgantas et al(2007) 
miR-203 1.103917 UD Epidermal differentiation Yi et al(2008) 
miR-206 1.563997 1.063436 Myogenic cells 
Rao et al(2006), Kim et 
al(2006) 
miR-124 0.707948 0.458512 Brain specific Landgraf et al (2007) 
miR-126-3P 1.455875 UD Endothelial cells Fish et al(2008) 
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miR-133a 2.509492 1.42217 Cardiac cells Ivey et al(2008) 
miR-133b 2.094272 1.293552 Cardiac cells Ivey et al(2008) 
miR-34a 3.763473 4.818876 cell cycle arrest He et al(2007), Yamakuchi et 
al(2008), Chang et al(2007). 
Raver-Shapria et al(2007) 
miR-34b-5P 1.869908 UD cell cycle arrest He et al(2007) 
miR-34c-5P 1.726008 1.060224 cell cycle arrest He et al(2007) 
Table 3 Selected miRNAs expression profile during SMC differentiation from 
ES cells 
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Figure 10 Real-Time PCR analysis of miR-34a during SMC differentiation  
Undifferentiated ES cells were seeded on collagen coated flasks and cultured for 2, 4, 
6 and 8 days in differentiation medium. Day 0 represented undifferentiated ES cells. 
Cells were harvested at indicated time points to extracted total RNA including small 
RNA, and subjected to real-time PCR analysis. The data represent mean ± SEM of 
three independent experiments. * P<0.05 (verse day 0) 
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4.1.2 Investigating the role of miR-34a in SMC differentiation in 
vitro by miRNA gain/loss-of function analyses 
To investigate whether miR-34a promotes SMC differentiation, gain-of-function 
experiments were carried out by using Pre-miR™ mmu-miR-34a miRNA Precursor 
(Ambion) in differentiating ES cells as described in Chapter 2. Real-time PCR result 
showed that miR-34a expression was significantly increased after transfection, and 
miR-34a overexpression significantly up-regulated the expression of SMC-specific 
genes, such as SMαA, SH22α, h1-calponin and SM-myh11 (Figure 11A). Western 
blot analysis was also carried out to determine whether protein level of SMC markers 
was affected by overexpression of miR-34a during SMC differentiation. Data from 
Figure 11B showed that the protein levels of SMαA and SM-MHC were significantly 
up-regulated in miR-34a overexpression groups, as compared to negative control 
group  
 
To further test whether activation of miR-34a is essential for SMC differentiation, 
lose-of-function experiments were performed by using Anti-miR™ miR-34a 
inhibitor (Ambion) in differentiating ES cells. As miR-145 is a well-known SMC 
differentiation related miRNA, MISSION® microRNA Inhibitor has-miR-145-5p 
(Sigma-Aldrich) was used as positive control. The study showed that knockdown of 
miR-34a during differentiation inhibited the expression of SMC specific markers at 
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both RNA (Figure 12A) and protein levels (Figure 12B). Taken together, these data 
suggest that miR-34a plays an important role in SMC differentiation from ES cells. 
 
To further understand the molecular mechanism by which miR-34a regulated SMC 
differentiation from ES cells, differentiating ES cells were transfected with miR-34a 
precursor or negative control, and subjected to microarray analyses performed by 
GENERGY BIO. (Beadchip: mouseWG-6_V2_0_R311278593-A;) to examine the 
gene expression profiling that affected by miR-34a overexpression during SMC 
differentiation. Data (Listed in appendix) demonstrated that a panel of SMC specific 
genes such as CNN1, Acta2, Tagln2, Aebp1, Smtn, Des, Cald1, Mylk Myh11 and Vcl 
(highlighted) were positively regulated by miR-34a overexpression. More 
importantly, several SMC transcription factors including SRF, Myocardin and 
MEF2c were also up-regulated by miR-34a, alongside SirT1. Therefore, Real-Time 
PCR and western blot analysis on differentiating SMCs with miR-34a 
overexpression or inhibition were performed to confirm the findings from microarray. 
The result suggested that overexpression of miR-34a up-regulated SRF, myocardin 
and MEF2C, while knockdown of miR-34a down-regulated these genes (Figure 13A 
and Figure 14A). Similar results were obtained from protein analysis, while protein 
levels of SRF and MEF2c were up-regulated by miR-34a overexpression but 
down-regulated by knockdown of miR-34a (Figure 13B and Figure 14B). 
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Figure 11 miR-34a overexpression up-regulates the expression of SMC markers 
in SMC differentiation 
Undifferentiated ES cells were seeded on collagen coated flasks and cultured in 
differentiation medium. Day 2~3 differentiating ES cells were transfected with 
miR-34a precursor or negative control and cultured for another 48 to72 hours. Cells 
were harvested and subjected to real-time PCR and western blot analysis, 
respectively. (A) Real-time PCR analysis of SMC gene expression after miR-34a 
overexpression. (B) Western bolt analysis of SMC markers after miR-34a 
overexpression. miR-145 precursor was included as positive control. α-tubulin was 
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used as housekeeping protein. The data presented here are representative or mean ± 
SEM of three to six independent experiments. *P<0.05 (versus control) 
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Figure 12 miR-34a knockdown inhibit expression of SMC markers in SMC 
differentiation 
Day 2~3 differentiating ES cells were transfected with miR-34a inhibitor or negative 
control. miR-145 inhibitor was included as positive control. Differentiating ES cells 
were seeded on collagen coated flasks and cultured in differentiation medium for 48 
hours after transfection. Cells were harvested and subjected to real-time PCR and 
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western blot analysis, respectively. (A) Real-Time PCR analysis of SMC gene and 
miRNA expression level in miR-34a knockdown experiment. (B) Western blot 
analysis of SMC markers protein expression with inhibition of miR-34a, where 
α-tubulin was used as housekeeping protein. The data presented here are 
representative or mean ± SEM of three to six independent experiments. *P<0.05 
(versus control) 
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Figure 13 Overexpression of miR-34a positively regulated SMC specific 
transcription factors 
Day 2~3 differentiating ES cells were transfected with miR-34a precursor or 
negative control and cultured for further 48 hours. Cells were harvested and 
subjected to real-time PCR and western blot analysis, respectively. (A) Real-Time 
PCR analysis of SMC transcription factor gene expression, which was up-regulated 
in miR-34a overexpression experiments. (B). Western blot analysis of SRF and 
MEF2c protein level. Protein level of SRF and MEF2c was up-regulated by 
overexpression of miR-34a. miR-145 precursor treatment was included as positive 
control. α-tubulin was used as housekeeping protein. The data presented here are 
representative or mean ± SEM of three independent experiments. *P<0.05 (versus 
control) 
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Figure 14 Knockdown of miR-34a down-regulated the expression levels of SMC 
transcription factors 
Day 2~3 differentiating ES cells were transfected with miR-34a inhibitor or negative 
control. Differentiating ES cells were cultured in collagen coated flasks in 
differentiation medium for 48 hours after transfection. Cells were harvested and 
subjected to real-time PCR and western blot analysis, respectively. (A) Real-Time 
PCR analysis of SMC transcription factor gene expression from miR-34a knockdown 
experiments. (B) Western blot analysis of SMC transcription factor protein level 
from miR-34a knockdown experiments. The data presented here are representative or 
mean ± SEM of three independent experiments. *P<0.05 (versus control) 
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4.1.3 miR-34a is involved in SMC differentiation in vivo 
To carry out in vivo cell implantation study, miR-34a overexpressing (pLL3.7 –
GFP-miR-34a) and control (pLL3.7-GFP) ES cell lines were generated by using 
miR-34a overexpression (pLL3.7–GFP-miR-34a) and control (pLL3.7-GFP) 
lentivirus respectively, as described in chapter 2. GFP-positive cells with high purity 
were sorted out (Figure 15A) and maintained in ES cell culture medium. No 
significant differences were observed between sorted cells and their parent 
undifferentiated ES cells in terms of morphology, self-renew and pluripotency when 
they were maintained in ES cell culture medium for up to 5 passages. The miR-34a 
overexpressing and control ES cells were induced to differentiate SMCs using in 
vitro SMC differentiation method as described above. Cells were harvested at day 0 
and 8 post-differentiation and subjected to real-time PCR and flow cytometry 
analysis, respectively. Compared to control ES cells, the expression of miR-34a in 
miR-34a overexpression ES cells was slightly higher at day 0 (undifferentiated cells), 
but significantly increased at day 8 of differentiation (Figure 15B), suggesting that 
miR-34a expression was successfully up-regulated in these cells during SMC 
differentiation. Importantly, more SMCs were differentiated from miR-34a 
overexpression ES cells as compared with control ES cells at day 8 (Figure 15C), 
further confirming the important role of miR-34a in SMC differentiation. 
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To determine the functional importance of miR-34a in SMC differentiation in vivo, 
pLL-3.7-GFP-miR-34a and pLL-3.7-GFP ES cells were subcutaneously injected into 
C57BL/6J mice with 100ng/ml of PDGF-BB to promote in vivo SMC differentiation 
as described in chapter 2. As expected, Results from Immunofluorescence staining 
showed that the majority of cells within Matrigel implants from both treatments were 
GFP-positive (Green signal), indicating its exogenous origins. Importantly, more 
SM-MHC positive cells were observed in the implants of miR-34a overexpressing 
ES cells (Figure 16A and B). Furthermore, the expression of miR-34a, SMαA, 
SM-MHC and SirT1 in Matrigel implants of miR-34a overexpression ES cells was 
significantly higher than that of control ES cells, as demonstrated in both real-time 
PCR (Figure 17A) western blot analysis (Figure 17B). Taken together, these data 
suggest an important role of miR-34a in SMC differentiation from ES cells in vivo. 
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Figure 15 Generation of miR-34a over expression ES cells and differentiation 
towards SMCs 
(A) miR-34a overexpression and control ES cell line were generated as described in 
chapter 2. Higher than 94% of sorted cells were GFP-positive as examined by flow 
cytometry analyses . (B) ES cell lines were cultured in collagen coated flasks in 
differentiation medium for 8 days. Cells were harvest and subjected to real-time PCR 
analysis. *P<0.05 (versus day 0), #P<0.05 (pLL3.7-GFP-miR-34a versus pLL3.7 
GFP). (C) After 8 days of differentiation, more SMCs were differentiated from 
miR-34a overexpressing ES cells. Data presented here are representative or mean 
±SEM of three independent experiments.  
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Figure 16 miR-34a promotes SMC differentiation from ES cells in vivo 
Matrigel plugs implanted with miR-34a overexpressing (pLL-GFP-miR-34a) or 
control (pLL-3.7-GFP) ES cells were harvested, sectioned and subjected to 
immunofluorescence staining using antibodies against GFP and SM-MHC or SirT1 
alone. (A) Representative images from immunofluorescence staining, Green: GFP or 
SirT; Red: SM-MHC; Blue: DAPI. (B) Quantitative data of the percentage of 
SM-MHC positive cells. The percentage of GFP-labeled SM-MHC positive cells per 
field was counted by two trained independent investigators blinded to the treatment 
from four random high power fields (200x) in each sections, three sections from each 
implant and four implants from each group.*P<0.05 
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Figure 17. SMC differentiation was up-regulated by miR-34a overexpression in 
vivo 
Matrigel plugs implanted with miR-34a overexpressing (pLL-GFP-miR-34a) or 
control (pLL-3.7-GFP) ES cells were harvested. Total RNA including small RNA, 
and protein were extracted from Matrigel implants and subjected to real-time PCR 
(A) and western blot (B) analysis, respectively. α-tubulin was used as housekeeping 
protein. The data presented here are representative or mean ± of four Matrigel 
implants. *P<0.05 
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4.1.4 miR-34a also plays an important role in SMC differentiation 
from human ES cells. 
As the current result suggested that miR-34a plays an important role in SMC 
differentiation from mouse ES cells, it was still not clear that whether miR-34a was 
involved in SMC differentiation from human ES cells. To address this issue, human 
ES cells were induced to differentiate towards SMC by using a similar differentiation 
method as used in the mouse ES cell differentiation study. The result demonstrated 
that human ES cells can be successfully differentiated into SMCs, based on the data 
from real-time PCR (Figure 18A), Western blot (Figure 18B), immunofluorescence 
staining (Figure 18C) and flow cytometry (Figure 18D) analyses. miR-34a level was 
also significantly increased during SMC differentiation from human ES cells (Figure 
19A). Similar to the result obtained from murine ES cells, SMC markers was 
up-regulated by miR-34a overexpression (Figure 19B and C), while miR-34a 
knockdown inhibited SMC marker expression in differentiating human ES cells 
(Figure 19D and E). These finding further confirmed a critical role of miR-34a in 
human SMC differentiation. 
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Figure 18 SMC differentiation from human ES cells in vitro 
Undifferentiated human ES cells were seeded into collagen coated flasks and 
cultured in differentiation medium for 3, 5, 7 and 9 days respectively. Total RNA 
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(including small RNA) and protein were extracted and subjected to real-time PCR (A) 
and Western blot (B) analysis, respectively. Day 0 represented undifferentiated 
human ES cells. (C) Immunofluorescence analysis of SMαA expression in 
differentiated SMCs (day 9). Representative of phase-control image and IgG control 
were also included. (D) Flow cytometry analyses of SMC markers expression in 
differentiated SMCs from human ES cells by using antibodies against SMαA or 
SM-MHC. The data presented here are representative of mean ± SEM of three 
independent experiments. *P<0.05 (versus day 0) 
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Figure 19 SMC differentiation from human ES cells can be regulated by 
miR-34a 
(A) Expression of miR-34a was up-regulated during SMC differentiation from 
human ES cells. Undifferentiated human ES cells were seeded into collagen coated 
flasks and cultured in differentiation medium for 3, 5, 7 and 9 days, respectively. 
Total RNA (including small RNA) was extracted and subjected to real-time PCR 
analysis. *P<0.05 (verse day 0). (B-E) Day 2 ~3 differentiating human ES cells were 
transfected with miR-34a precursor or inhibitor, or respective negative controls then 
cultured in SMC differentiation medium for 48 to 72 hours after transfection. Total 
RNA (including small RNA) and protein were extracted and subjected to Real-Time 
108 
 
PCR (B and D) and Western blot (C and E) analysis, respectively. Expression of 
SMC specific marker was up-regulated by miR-34a overexpression (B and C), and 
inhibited by knockdown of miR-34a (D and E).The data presented here are 
representative or mean ± of three independent experiments (n=3). *P<0.05 (versus 
negative control). 
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4.2 SirT1 is identified as the mRNA target for miR-34a in 
SMC differentiation from ES cells 
To further investigate the mechanism by which miR-34a regulates SMC 
differentiation from ES cells, potential mRNA targets of miR-34a were scrutinized 
and SirT1 was predicted as one of the top targets of miR-34a in several 
computational algorithmic databases, such as Targetscan (www.targetscan.org), 
pictar (www.pictar.mdc-berlin.de), and miRanda (www.microrna.org).  Two highly 
conserved binding sites for 5’ end (code sequence) of miR-34a were located on the 
3’UTR of SirT1 (Figure 21A)  
 
4.2.1 SirT1 was selected as potential mRNA target for miR-34a 
To investigate whether SirT1 is the mRNA target for miR-34a, SirT1 gene expression 
was analyzed during SMC differentiation from ES cells. Unexpectedly, SirT1 gene 
expression was up-regulated (Figure 20A) and displayed a positive correlation with 
expression of miR-34a during SMC differentiation (Figure 10), suggesting that 
miR-34a may positively regulated SirT1 gene expression. This hypothesis was 
supported by the findings that SirT1 gene and protein levels were significantly 
up-regulated by miR-34a overexpression, while inhibition of miR-34a 
down-regulated SirT1 expression levels (Figure 20B and C). These data suggested 
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that SirT1 is positively regulated by SirT1 directly or indirectly. 
 
 
Figure 20 SirT1 is the potential mRNA target for miR-34a 
(A) Undifferentiated ES cells were seeded on collagen coated flasks and cultured in 
differentiation medium for 2, 4 and 6 days. Day 0 represented undifferentiated ES 
cells. Total RNA was extracted and subjected to Real-Time PCR analyses. SirT1 
expression was up-regulated during SMC differentiation. (B-C) SirT1 is positively 
regulated by miR-34a. Day 2~ 3 differentiating ES cells were transfected with 
miR-34a precursor or miR-34a inhibitor with respective negative control then 
cultured in differentiation medium for 48 hours. Total RNA (including small RNA) 
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and protein were extracted and subjected to Real-Time PCR (B) and Western blot (C) 
analyses, respectively. The data presented here are representative or mean ± S.E.M. 
of three to four independent experiments. *P<0.05 (versus day 0) in (A). *P<0.05 
(treatment verse control) in (B and C)  
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4.2.2 Identifying SirT1 as mRNA target for miR-34a 
To further confirm whether SirT1 is the mRNA target for miR-34a during SMC 
differentiation, the 3’UTR of SirT1 which contained two binding sites for miR-34a 
was cloned into a luciferase reporter (pmiR-Luc-SirT1-WT). This reporter was 
co-transfected with miR-34a precursor or negative control into differentiating ES 
cells. Result from miRNA reporter assay showed that the activity of luciferase from 
construct harboring the 3’UTR was significantly up-regulated by overexpression of 
miR-34a. To better understand this result, mutation of the binding sites for miR-34a 
on the 3’UTR of SirT1 from pmiR-Luc-SirT1-WT was carried out to generate 
luciferase reporter containing individual binding site mutation 
(pmiR-Luc-SirT1- BS1mu  and pmiR-Luc-SirT1- BS2mu ), or dual binding sites 
mutation (pmiR-Luc-SirT1-BS1/2mu) by site-direct mutagenesis. These miRNA 
reporters were transfected into differentiating ES cells with miR-34a precursor, and 
the result showed that luciferase activities of reporter containing  binding site 2 
mutation(BS2mu) or dual binding sites mutation(BS1/2mu)  were not up-regulated 
by miR-34a overexpression, indicating that the binding site 2 is mainly responsible 
for the up-regulation of SirT1 3’UTR reporter luciferase activity which mediated by 
miR-34a overexpression. Taken together, these data has firmly confirmed that SirT1 
is the mRNA target, which is positively regulated by miR-34a during SMC 
differentiation.   
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Figure 21 SirT1 is identified as the mRNA target for miR-34a during SMC 
differentiation 
(A) Two potential binding sites for miR-34a on 3’UTR of SirT1 predicted by 
Targetscan are depicted in this illustration. (B) miR-34a binding site 2 on 3’UTR of 
SirT1 is required for miR-34a mediated SirT1 gene activation. Wild type SirT1 
3’UTR reporter (pmiR-Luc-SirT1-WT) or three mutants (pmiR-Luc-SirT1-BS1mu, 
pmiR-Luc-SirT1-BS2mu and pmiR-Luc-SirT1-BS1/2mu) were co-transfected with 
miR-34a precursor or negative control into day 2~3 differentiating ES cells and 
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luciferase activity was measured 48 hours after transfection. Reporter luciferase 
activities were up-regulated by miR-34a overexpression in WT and BS1mu group, 
but not in BS2mu or BS1/2mu group. The data presented here are mean ± S.E.M. 
of four independent experiments. *P<0.05 (treatment versus control) # P<0.05 
(binding site mutants versus wild type). 
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4.3 miR-34a regulates SirT1 and cell cycle during SMC 
differentiation 
Current data suggested that SirT1 is the mRNA target of miR-34a and can be 
up-regulated by miR-34a during SMC differentiation. However, the mechanism by 
which miR-34a positively regulates SirT1 is still not clear and requires more 
investigation.  
4.3.1 miR-34a differently regulates SirT1 gene expression in 
undifferentiated ES cells and differentiated SMCs 
In order to investigate if miR-34a up-regulated the expression of its target gene, 
SirT1, during SMC differentiation is cellular context specific, miR-34a 
over-expression or inhibition experiments and luciferase activity assays were 
conducted in naïve stem cells (undifferentiated ES cells) and terminally differentiated 
SMCs {It has been  reported that day 8 differentiated SMCs are fully/terminally 
differentiated SMCs(Xiao et al., 2009)}, respectively. Interestingly, the data showed 
that SirT1 3’UTR reporter activity was significantly suppressed by miR-34a 
overexpression, but up-regulated by inhibition of miR-34a in undifferentiated ES 
cells (Figure 22A). As expected, SirT1 3’UTR reporter activity was significantly 
up-regulated by miR-34a overexpression, and decreased by knockdown of miR-34a 
in terminally differentiated SMCs (Figure 22B). These findings suggested that 
miR-34a regulates SirT1 gene expression is cellular context dependent.   
116 
 
 
Figure 22 SirT1 3’UTR reporter activity in naive stem cell or terminally 
differentiate SMCs. 
(A) Undifferentiated ES cells were transfected with pmiR-Luc-SirT1-WT as well as 
miR-34a precursor, miR-34a inhibitor or respective negative control. Luciferase 
activity was measured 48 hours after transfection. SirT1 3’UTR reporter activity was 
suppressed by miR-34a overexpression but increased by inhibition of miR-34a in 
naive stem cell. (B) Day 8 differentiated SMCs were transfected with 
pmiR-Luc-SirT1-WT as well as miR-34a precursor, miR-34a inhibitor or respective 
negative control. Luciferase activity was measured 48 hours after transfection. SirT-1 
3’UTR reporter activity was up-regulated by miR-34a overexpression while 
knockdown of miR-34a decrease the reporter activity. The data presented here are 
mean ± S.E.M. of four independent experiments. *P<0.05 (versus respective 
controls). 
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4.3.2 miR-34a binding site alone is not sufficient for miR-34a 
mediated SirT1 gene expression. 
As the result showed that miR-34a binding sites on 3’UTR of SirT1 are required for 
miR-34a mediated SirT1 gene expression (Figure 21), the next step is to determine 
whether miR-34a binding site alone is sufficient for this regulation. A luciferase 
reporter was generated with an artificial binding site for miR-34a, but without 
surrounding RNA sequence and structure of SirT1 3’UTR, designated as 
pmiR-Luc-miR-34a binding site. The reporter was transfected into differentiating ES 
cells with miR-34a precursor or negative control. Data from Figure 23 showed that 
miR-34a can only slightly up-regulated the reporter activity but not reached 
significance. This result suggests that the surrounding RNA sequence and/or 
structure of SirT1 3’UTR are also required for miR-34a mediated Sirt1 
up-regulation.  
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Figure 23 miR-34a binding site alone is not sufficient for SirT1 up-regulation  
pmiR-Luc-miR-34a binding site was generated as described in chapter 2 and 
transfected into day 2 differentiating ES cells in 24-well plate with miR-34a 
precursor or negative control. Luciferase assay was performed 48 hours after 
transfection. No significant difference on reporter activity was observed between 
control and miR-34a overexpression group. The data presented here are S.E.M. of 
three independent experiments. 
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4.3.3 miR-34a specifically up-regulates SirT1 during SMC 
differentiation   
MECP2 has been suggested to play an important role in SMC differentiation from ES 
cells (personal communications), and it has been reported that ZEB1 is involved in 
endothelial cell differentiation from human ES cells (Luo et al., 2013). To investigate 
whether regulation of SirT1 by miR-34a is a specific but not globe effect during 
SMC differentiation, MECP2 (target gene for miR-22) and ZEB1 { target gene for 
miR-200C/150 (Luo et al., 2013)} luciferase reporters were  transfected into 
differentiating ES cells combined with miR-34a precursor. Luciferase assay showed 
that there was no effects of miR-34a overexpression on neither reporter (Figure 24), 
further confirming that miR-34a specifically up-regulates SirT1 expression during 
SMC differentiation.  
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Figure 24 Other miRNA reporter were not affected by miR-34a over-expression 
MECP2 reporter and ZEB1 reporter were transfected into day 2 differentiating ES 
cells with miR-34a precursor or negative control. Luciferase assay was performed 48 
hours after transfection. No significant difference on luciferase activity between 
treatment and control. The data presented here are mean ± S.E.M. of three 
independent experiments. 
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4.3.4 miR-34a promotes cell cycle arrest at G0/1 in differentiating ES 
cells 
It has been reported that miRNA-target gene regulatory machinery will switch from 
translation repression to activation when cells are arrested at G0/1 phase, and 
miRNAs can regulates target gene translation activation in quiescent cells(Vasudevan 
et al., 2007, Vasudevan et al., 2008). Also, miR-34a has been reported to play an 
important role in regulating cell cycle in certain cell line (Sun et al., Cole et al., 2008, 
Chang et al., 2007). In this study less cell numbers were observed in miR-34a 
overexpression treatment during SMC differentiation (Figure 25). To investigate 
whether miR-34a is involved in cell cycle regulation during SMC differentiation, 
undifferentiated ES cells and differentiating SMCs were subjected to cell cycle 
analyses. The result showed that differentiating cells were gradually arrested at G0/1 
phase during SMC differentiation (Figure 26). More importantly, this cell cycle arrest 
can be enhanced by miR-34a overexpression (Figure 27A), indicating that miR-34a 
may be involved in regulation of cell cycle during SMC differentiation. These 
findings were further confirmed by apoptosis analysis (Figure 27B) and BrdU 
incorporation assays (Figure 27C), which showed that miR-34a has no significant 
impact on cell apoptosis or death, and much less cells were entering S-phase upon 
miR-34a overexpression. 
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To further confirm whether up-regulation of SirT1 gene expression by miR-34a is 
specific to G0/1 cell cycle stage, differentiating ES cells were arrested at G0/1 phase 
by cell cycle arrest inducer aphidicolin and luciferase activity assays were performed. 
The result suggested that incubation of differentiating ES cells with 2µg/ml 
aphidicolin significantly increased cell cycle arrest at G0/G1 phase, and such arrest 
was further enhanced by miR-34a overexpression (Figure 28A). As a result, SirT1 3’ 
UTR reporter activity was significantly increased by aphidicolin induced cycle cell 
arrest at G0/G1 phase and miR-34a overexpression in a similar manner (Figure 28B). 
Taken together, these data suggested that the miR-34a induced cell cycle arrest at 
G0/1 is, at least partially, responsible for the up-regulation of SirT1 during SMC 
differentiation. 
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Figure 25 Less cell numbers were observed in the miR-34a over-expressing cells 
Day 2~3 differentiating ES cells were transfected with miR-34a precursor or 
negative control and cultured in differentiation medium for 48 to 72 hours. (A) 
Representative microscopy images of differentiating ES cells with or without 
miR-34a overexpression. (B) Cells were dissociated into single cell suspension by 
trypsin-EDTA and counted by using a hemocytometer. The cells numbers were 
counted by two trained independent investigators blinded to the treatment, from 3 
flasks for each treatment at indicated time point. *P<0.05(versus control) 
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Figure 26 Cell cycle analysis during SMC differentiation 
Undifferentiated (Day 0) ES cells were seeded on collagen coated flasks and cultured 
in differentiation medium for 2, 4, 6 and 8 days. Cells were harvested and subjected 
to cell cycle analysis. Representative of flow cytometry histogram and percentages of 
each cell cycle phase (G0/1, S and G2/M) were presented here. The data presented 
here are representative or mean ± S.E.M. of three independent experiments *P<0.05 
(versus day 0) 
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Figure 27 miR-34a promotes cell cycle arrest at G0/1 and inhibits cell 
proliferation 
Day 2~3 differentiating ES cells were transfected with miR-34a precursor or 
negative control and cultured in differentiation medium for 48 hours. Cells were 
harvested and subjected to cell cycle (A), apoptosis (B) and BrdU incorporation (C) 
analyses, respectively. (A) miR-34a overexpression significantly promoted cell cycle 
arrest at G0/G1 phase. (B) miR-34a overexpression had no significant impact on cell 
apoptosis and death during SMC differentiation. (C) miR-34a overexpression 
inhibited differentiating ES cells into S-phase. The data presented here are 
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representative or mean ± S.E.M. of three to four independent experiments. 
*P<0.05(versus control)  
 
 
Figure 28 miR-34a mediated SirT1 gene activation was further enhanced by 
G0/G1 cell cycle arrest inducer 
Sirt1 3’UTR wild type reporter was transfected into day 2 ~3 differentiating ES cells 
with miR-34a precursor or negative control and cultured for further 24 hours. 2µg/ml 
of aphidicolin or same amount of carrier vehicle (ethanol) was added into culture 
medium and incubated for 24 to 28 hours. Cells were harvested and subjected to cell 
cycle and luciferase assay. (A) Aphidicolin induced cell cycle arrest at G0/1 phase 
can be further enhanced by miR-34a overexpression. (B) miR-34a overexpression 
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further up-regulated SirT1 gene expression in the presence of G0/G1 inducer 
aphidicolin. The data presented here are mean ± S.E.M. of three independent 
experiments. *P<0.05 (aphidicolin versus vehicle), #P<0.05 (miR-34a versus 
control).   
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4.3.5 Less miR-34a and SirT1 mRNA were incorporated into Ago 
2-RISC complex upon differentiation 
Ago 2 belongs to Argonaute proteins family. Ago 2 is one of the key components of 
RISC and have a critical role in miRNA induced gene silencing (Meister, 2013). To 
further investigate the molecular mechanism by which miR-34a up-regulates SirT1 
gene expression during SMC differentiation, undifferentiated and differentiated 
SMCs were harvested and subjected to RNA-IP assays with antibody against Ago 2. 
The result showed that the enrichments of miR-34a and SirT1 3’UTR RNA 
(spanning around miR-34a binding sites 1 and 2) in undifferentiated ES cells were 
much higher than that of differentiated SMCs (Figure 29), indicating that less 
miR-34a and SirT1 were loaded into Ago 2 -RISC complex during SMC 
differentiation   
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Figure 29 Less miR-34a and SirT1 were loaded onto Ago 2-RISC complex 
during SMC differentiation  
Undifferentiated ES cells and differentiated SMCs were harvested and then subjected 
to RNA-IP assay with antibody against Ago 2 or normal rabbit IgG, respectively. 
Real-Time PCR amplification of SirT1 coding region was included as additional 
control for specific SirT1 3’UTR enrichment. The data presented here are mean ± 
S.E.M. of three independent experiments. *P<0.05  
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4.4 Role of SirT1 in miR-34a induced SMC differentiation  
As described above, SirT1 has been proved to be the mRNA target for miR-34a and 
up-regulated by miR-34a upon SMC differentiation. However, the role of SirT1 
during SMC differentiation is still unclear, which requires further investigation in 
this section.  
 
4.4.1 SirT1 activation is required for miR-34a mediated SMC 
differentiation 
To investigate the potential role of SirT1 during SMC differentiation, SirT1 
overexpression experiments were conducted in differentiating ES cells by using 
SirT1 overexpressing plasmid {pcDNA-3.1 SirT1, a kind gift from Dr. Hang Shi, 
Wake Forest University School of Medicine, North Carolina, USA (Yang et al., 
2010)}. Data showed that SMC specific marker expressions were significantly 
increased upon overexpression of SirT1 during SMC differentiation (Figure 30A and 
B), suggesting that SirT1 over-expression can recapitulate the effects of miR-34a 
during SMC differentiation from ES cells. This finding was further confirmed by 
SirT1 agonist treatments. Resveratrol, a well-characterized SirT1 agonist (Borra et al., 
2005), has been reported to promote osteogenic differentiation of mesenchymal stem 
cell (Shakibaei et al., 2012, Tseng et al., 2011) or phenotypic switching of VSMC 
(Thompson et al., 2014). The result from resveratrol experiments suggested that 
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resveratrol significantly increased SMC specific gene expression with the best 
concentration of 5µM (Figure 30C), further supporting SirT1 plays an important role 
during SMC differentiation. 
 
To further confirm the hypothesis that SirT1 activation is required for miR-34a 
mediated SMC differentiation, control (pLL3.7-GFP) or miR-34a overexpressing 
(pLL3.7-GFP-miR-34a) ES cells were induced to differentiate into SMCs for 4 days 
then subjected to SirT1 specific inhibitor treatment. Data shown in Figure 31A 
revealed that inhibition of SirT1 alone significantly decreased SMC gene expression, 
while miR-34a overexpression up-regulated SMC marker. More importantly, 
inhibition of SirT1 almost completely abolished SMC specific gene up-regulation 
induced by miR-34a overexpression. Such finding was further confirmed by SirT1 
knockdown experiments using SirT1 specific siRNA, suggesting that miR-34a 
up-regulates SMC gene expression through activation of SirT1 (Figure 31B). Taken 
together, SirT1 is involved in SMC differentiation and the activation of SirT1 is 
critical for miR-34a induced SMC gene up-regulation. 
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Figure 30. SirT1 overexpression or activation promotes SMC differentiation 
(A and B) Day 2~3 differentiating ES cells were transfected with Sirt1 
overexpressing (pcDNA 3.1-SirT1) or control (pcDNA 3.1) plasmids and cultured in 
differentiation medium for 48 to 72 hours. Cells were harvested and subjected to 
Real-Time PCR (A) or Western blot (B) analysis, respectively. (C) Resveratrol 
promotes SMC gene expressions. Undifferentiated ES cells were induced to SMC 
133 
 
differentiation for 3 days, then resveratrol or same amount of carrier vehicle (ethanol) 
was added into culture medium and incubated for further 24 hours. Cells were 
harvested and subjected to Real-Time PCR analysis. The data presented here are 
representative or mean ± S.E.M. of three independent experiments. *P<0.05 
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Figure 31 Inhibition/knockdown of SirT1 abolished SMC specific gene 
up-regulation induced by miR-34a overexpression 
(A) Inhibition of SirT1 abolished SMC gene up-regulation induced by miR-34a 
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overexpression. Control (pLL3.7-GFP) or miR-34a overexpressing 
(pLL3.7-GFP-miR-34a) ES cells were induced to differentiate into SMCs for 4 
days, then incubated with SirT1 specific inhibitor (500nM, EMD Millipore, 
566322) or carrier vehicle (DMSO) for 6 or 12 hours. Total RNAs wereharvested 
and subjected to Real-Time PCR analysis. (B)Knockdown of SirT1 eliminated 
the effect of miR-34a overexpression on SMC gene expression. Day 2 ~3 
differentiating ES cells were co-transfected with miR-34a precursor, SirT1 
siRNA or related control (including miRNA negative control and siRNA control), 
and cultured in differentiation medium for 48 hours. Cells were harvested and 
subjected to Real-Time PCR analysis. Data presented here are mean ± S.E.M. of 
three to four independent experiments. *P<0.05 (versus related control); #P<0.05 
(4
th
 columns versus 3
rd
 columns). 
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4.4.2 SirT1 regulates SMC transcription factors 
SRF, MEF2C and Myocardin are well-known transcription factors for regulating 
SMC gene expression and cardiovascular system development. Results from this 
study have already suggested that miR-34a can regulate these transcription factors, 
and SirT1 activation is required for miR-34a mediated SMC gene up-regulation. To 
investigate whether SirT1 mediates SMC differentiation through regulation of these 
transcription factors and their underlying pathways, gene expression levels of SRF, 
MEF2c and Myocardin were examined in SirT1 overexpression experiment. Figure 
32A revealed that by overexpressing SirT1, expression levels of SRF, MEF2c and 
Myocardin gene were significantly increased, suggesting SirT1 may have a direct 
role in regulation of these transcription factors during SMC differentiation. Such 
notion was further supported by SRF, MEF2c or Myocad gene reporter luciferase 
activity assays. Differentiating ES cells were transfected with SRF, MEF2c or 
Myocad gene reporter plasmids {pGL3-Luc-SRF, pGL3-Luc-MEF2c and 
pGL3-Luc-Myocd; Generated from previous study (Huang et al., 2013)} combined 
with SirT1 overexpression, and luciferase activity assays were conducted. The result 
showed that SirT1 overexpression significantly increased SRF, MEF2c and Myocd 
gene promoter activities (Figure 32B), suggesting that SirT1 may activate 
transcriptional activity of these three genes.  
 
137 
 
Furthermore, ChIP assays with SirT1 antibody were carried out to investigate 
whether SirT1 can directly bind to the promoters of SRF, MEF2c and Myocd, and the 
potential binding region(s) for SirT1 within these three gene promoters. A set of 
specific primers (4 paris) spanning through the respective promoter regions of SRF, 
MEF2c and Myocad as described in previous study (Huang et al., 2013) were used in 
preliminary study and the best primer pairs were chosen in the following experiments. 
Figure 33 showed that SirT1 directly binds to the promoter regions between -1393 
and -1274 of SRF gene, -1335 and -1263 of MEF2c gene and -708 and -620 of 
Myocd gene, respectively. It is also demonstrated that the binding activity was 
significantly enhanced by overexpression of SirT1. Taken together, these data 
strongly suggested that SirT1 transcriptionally regulates SMC transcriptional factor 
gene expressions through directl binding to the promoter regions of these genes 
during SMC differentiation from ES cells. 
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Figure 32 SirT1 up-regulates SMC transcriptional factors  
Day 2 ~ 3 differentiating ES cells were transfected with control or SirT1 
overexpressing plasmid (A), or combined with indicated luciferase reporter (B). 
Cells were harvested 48 hours after transfection and then subjected to Real-Time 
PCR (A) or Luciferase assay (B). (A) SirT1 overexpression up-regulates SRF, 
Myocd and MEF2c expression. (B) SirT1 overexpression regulates the promoter 
activities of SMC transcription factor genes. The data presented here are mean ± 
S.E.M. of three to six independent experiments. *P<0.05 (versus control) 
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Figure 33 SirT1 directly binds to the promoter regions of SRF, MEF2c and 
Myocd genes. 
Day 2 ~3 differentiating ES cells were transfected with control (pcDNA 3.1) or SirT1 
overexpressing (pcDNA-3.1 SirT1) plasmids and cultured in differentiation medium 
for 48 hours. Cells were harvested then subjected to ChIP assays. ChIP assays were 
performed using antibody against SirT1 or normal rabbit IgG, respectively. 
Real-Time PCR amplifications of the adjacent regions were included as additional 
control for specific promoter enrichment. The data presented here are mean± S.E.M. 
of four independent experiments. *P<0.05 (versus control) 
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4.4.3 SRF binding site is required for SirT1 mediated SMC gene 
expression 
SirT1 has been showed to up-regulate SMC specific gene expression and SMC 
specific transcriptional factors during SMC differentiation from ES cells. To 
investigate if SirT1 overexpression will activate specific SMC gene transcription, 
luciferase activity assay was performed with reporter plasmid of SMαA 
(pGL3-Luc-SMαA) and SM22α (pGL3-Luc-SM22a) in differentiating ES cells, 
combined with SirT1 overexpression. Data from Figure 34 suggested that 
overexpression of SirT1 during SMC differentiation dramatically increased gene 
promoter activities of SMαA and SM22α, indicating that SirT1 can activate specific 
SMC gene promoter. SRF is a well-known SMC transcriptional factors and SRF 
binding element (CArG) within promoter region of SMC genes is required for 
transcriptional activation of SMC gene expressions(Miano, 2003). As SirT1 has been 
showed to up-regulate SRF and SMC gene promoter gene expression during SMC 
differentiation, the functional involvements of SRF binding element within SMC 
gene promoter in SirT1 mediated SMC gene expression needed to be investigated.  
 
To address this issue, luciferase assays using SRF binding site mutants 
(pGL3-Luc-SMaA-S Fmu and pGL3-Luc- SM22a -S Fmu) were carried out in 
differentiating ES cells combined with SirT1 overexpression. Data from Figure 34 
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showed that mutation of SRF binding element in pGL3-Luc-SMaA and pGL3-Luc- 
SM22a caused complete loss of their transcriptional activity in response to SirT1 
overexpression as compared with results from wild type reporter, suggesting SRF 
binding elements within SMC gene promoter region is responsible for SirT1 induced 
SMC gene up-regulation. 
 
Moreover, ChIP assays were conducted using antibodies against SirT1 or SRF in 
differentiating ES cells to further verify if SirT1 activates specific SMC gene 
transcription through direct binding to their promoters. The result revealed that SirT1 
directly bound to the region spanning around SRF binding element (CArG ) of 
SMαA and SM22α gene promoters, and such binding was dramatically reinforced by 
SirT1 overexpression (Figure 35A). Data from Figure 35B showed that SirT1 
overexpression significantly enhanced the binding capacity of SRF to gene 
promoters of SMαA and SM22α. Taken together, these finding demonstrated that 
SirT1 regulates specific SMC gene expression during SMC differentiation from ES 
cells through direct binding to the promoter region of SMαA and SM22α, and such 
binding ability can also be further enhanced by SirT1 overexpression. 
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Figure 34 SRF binding site is required for SirT1 mediating SMC gene 
expression 
Day 3~4 differentiating ES cells were co-transfected with wild type reporter 
(pGL3-Luc-SMαA and SM22α pGL3-Luc-SM22a), or mutants 
(pGL3-Luc-SMaA- S Fmu  and pGL3-Luc- SM22a - S Fmu  ), and SirT1 
overexpressing or control plasmids as indicated. Luciferase assays were performed 
48 hours after transfection. SirT1 overexpression significantly increases wild type 
reporter activities of SMαA and SM22α gene, but not in the respective mutants. The 
data presented here are mean ± ± S.E.M. of four independent experiments. *P<0.05 
(versus control) 
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Figure 35 SirT1 directly binds to specific SMC gene promoter regions and 
increases the binding ability of SRF to SMαA and SM22α 
Day 2 ~3 differentiating ES cells were transfected with SirT1 overexpressing 
(pcDNA 3.1-SirT1) or control (pcDNA 3.1) plasmids and cultured in differentiation 
medium for 48 hours. Cells were harvested then subjected to ChIP assays using 
antibodies against SirT1(A) or SRF(B), as well as related IgG antibodies. (A) SirT1 
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directly binds to the regions spanning around SRF binding element (CArG ) of 
SMαA and SM22α gene promoters. (B) SirT-1 overexpression increases SRF binding 
to the promoter regions of SMαA and SM22α genes. Real-Time PCR amplifications 
of the non-CArG regions were included as additional control for specific promoter 
DNA enrichment. The data presented here are mean ± S.E.M. of four independent 
experiments. *P<0.05 (versus control) 
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4.4.4 SirT1 inhibits H3K9 methylation around SMC gene promoters 
DNA and/or histone methylation is an important epigenetic gene regulation pathway.  
It is well-known that methylation of lysine H3K9 and H3K27 is closely associated 
with transcriptional repression (Rosenfeld et al., 2009), and SirT1 can regulate 
histone methylations in cancer (Liu et al., 2009, Liu and McCall, 2013). To 
investigate if SirT1 affects H3K9me3 expression levels during SMC differentiation, 
SirT1 overexpression experiments were conducted in differentiating ES cells and 
subjected to Western blot and Chip assays. Data showed that SirT1 overexpression 
had little effect on H3K9me3 protein expression (Figure 36A), however the 
enrichments of HK39me3 on SMαA and SM22α gene promoters with CArG regions 
were significantly inhibited by overexpression of SirT1 (Figure 36B), suggesting that 
SirT1 regulates SMC-specific gene expression at least partially through inhibiting 
H3K9 tri-methylation around SMC specific gene promoters. 
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Figure 36 SirT1 promotes SMC gene expression through inhibiting H3K9me3 
binding to SMC gene promoters. 
Day 2~3 differentiating ES cells were transfected with control (pcDNA 3.1) or SirT1 
overexpressing (pcDNA 3.1-SIrT1) plasmids and cultured in differentiation medium 
for 48 hours. Cells were harvested and subjected to Western blot analyses (A) or 
ChIP assays (B), respectively. (A) H3K9me3 protein levels were not affected by 
SirT1 overexpression. (B) SirT1 overexpression reduces H3K9me3 binding to the 
promoter regions of SMαA and SM22α. ChIP assays using antibody against 
H3K9me3 or normal mouse IgG, respectively. Real-Time PCR amplifications of 
non-CArG regions were included as additional control. The data presented here are 
representatives or mean ± S.E.M. of four independent experiments. *P<0.05 (versus 
control) 
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CHAPTER 5 Discussion 
The results obtained from this project advance our knowledge of the molecular 
mechanism mediating SMC differentiation by uncovering an important role of 
miR-34a in regulating SMC specific gene expression and SMC differentiation from 
mouse ES cells in vitro and in vivo. Such importance of miR-34a has also been 
confirmed in human SMC differentiation from stem cells. Surprisingly, SirT1 has 
been identified as the mRNA target of miR-34a, and the results demonstrated that 
miR-34a positively regulates its target gene, SirT1, during SMC differentiation from 
ES cells. Mechanistically, miR-34a is found to promote cell cycle arrest at G0/1 
phase, and a significant decreased incorporation of miR-34a and SirT1 RNA into 
Ago 2-RISC complex was observed upon SMC differentiation. Also, SirT1 is defined 
as a potential transcription activator of SMC specific gene regulation. Furthermore, 
the SRF binding site(s) within SMC specific gene promoters is required for SirT1 
mediated SMC gene transcriptional activation, and SirT1 regulates SMC 
transcription factors (SRF, MEF2c and Myocd) at transcriptional level. Finally, SirT1 
has been observed to regulate SMC gene expression through modulating the histone 
methylation status around SMC specific gene promoters. Taken together, data 
provided in the current study strongly suggests that miR-34a is a powerful SMC 
differentiation modulator by positive regulating its target gene, SirT1, a molecule 
functioning as a potential SMC-specific gene transcriptional activator. 
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5.1 SMC differentiation from ES cells 
ES cells are derived from the inner cell mass of a blastocyst stage embryo and hold 
the ability to differentiate various types of cells, including SMCs. SMCs play an 
important role in the embryonic development of cardiovascular system, as well as 
other organs and tissues. They also play critical roles in cardiovascular diseases, such 
as stroke, hypertension and atherosclerosis. Better understanding of the mechanism 
by which ES cells differentiate into SMCs not only contributes to extending our 
knowledge of cardiovascular system development and diseases, but also provides 
theoretical/technical information to the development of regenerative medicine and 
tissue engineering. SMC differentiation from stem cell is a complicated and poorly 
defined process regulated by various molecular signal pathways, which includes 
stimulation of ECM, growth factors, mechanical stress and other micro 
environmental milieu. Despite the process of SMCs differentiation from stem cells 
has been intensively studied, the understanding of mechanisms underlying SMC 
differentiation is still far from complete, especially in the fields of functional role of 
small non-coding RNAs, as revealed by recent studies. 
 
In a previous study by Xiao et al. (2007) revealed that collagen type IV can stimulate 
ES cells to differentiate into sca-1 positive cells then further differentiate into SMCs, 
which is mediated by collagen IV-integrin 𝛼1/𝛽1/𝛼𝑣 . In that study it was also 
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pointed out that collagen type I can potentially induce SMC differentiation from ES 
cells through similar pathway of collagen type IV. In the present study, one of the 
goals is to further confirming the hypothesis that similar to collagen type IV, collagen 
type I can also facility SMC differentiation from stem cells. Multiple SMC-specific 
markers including SMαA, SM22α, calponin and SM-MHC were applied in this 
project to examine if SMC differentiation has been realized. Determination of SMC 
differentiation from ES cells was carried out by detecting chosen SMC specific 
markers during differentiation. Data from Figure 6 showed that the gene expressions 
of SMC specific markers, including SMαA, SM22α, calponin and SM-MHC were 
significantly increased after 4 days into differentiation and reached maximum level at 
day 6, as compared to that of undifferentiated ES cells. mRNA levels of early SMC 
differentiation markers, such as SMαA and SM22α(Owens et al., 2004) were 
increased over 800 and 200 folds respectively, as compared with undifferentiated ES 
cells. Importantly, the expression levels of late/mature SMC differentiation markers 
including calponin and SM-MHC (Owens et al., 2004) over the differentiation period 
were over 40 times higher than that of undifferentiated ES cells. Nanog, OCT3/4 and 
KLF4 are key factors in maintaining self-renew, pluripotency and undifferentiated 
state of ES cells. As expected, the mRNA levels of these ES cell specific markers 
significantly decreased from day 2 of differentiation, and maintained over 50% 
reduction at day 8 of differentiation (Figure 7). 
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SRF, MEF2c and myocardin are well known SMC transcriptional factors and play 
critical roles in SMCs differentiation and/or mature SMCs phenotype switching.  
SRF can directly bind to CArG elements within the promoter regions of SMC 
specific gene, and recruits its cofactor: myocardin, to form SRF-mycoardin complex 
and work together with other transcription factors to regulate SMC differentiation 
(Cao et al., 2005, Dressel et al., 2001, Pagiatakis et al., 2012, Wang et al., 2003, 
Margariti et al., 2009, Owens et al., 2004, Wang et al., 2004, Xiao et al., 2010). It has 
been reported that SRF, MEF2c and myocardin were activated during collagen IV 
induced SMC differentiation (Margariti et al., 2009, Huang et al., 2013). Real-Time 
PCR analysis (Figure 8) showed that these transcriptional factors can also be 
triggered by collagen type I during SMC differentiation from ES cell. mRNA level of 
SRF and MEF2c started to increase from day 4 and reached maximum at day 6, 
while that of myocardin increased at a slightly later time but also significantly 
up-regulated at day 6 and expressed maximally at day 8. 
 
Protein levels of SMαA and calponin during SMC differentiation were detected by 
using Western blot analyzes, as presented in Figure 8. Both SMαA and calponin 
protein expressions were not detected at day 0 (undifferentiated ES cells), but strong 
signals were detected from day 6 samples. The protein expression of SMαA and 
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calponin appeared at slightly later time, as compared with mRNA level. These time 
differences in gene and protein expression are possible due to late translation from 
SMαA and calponin mRNA. 
 
Taken together, these data suggested collagen type I may act as similar function of 
collagen type IV in SMC differentiation from ES cell, further supporting the findings 
from Xiao et al. (2007). Furthermore, Real-Time PCR result showed that 
undifferentiated stem cell markers were significantly down-regulated from day 2, 
which indicated that the early SMC differentiation from ES cell may start after 2 
days into the SMC differentiation model. It is further confirmed by the results from 
gene expression level of SMC specific markers, which started to up-regulate from 
day 2, increased significantly at day 4 and reached maximum level at day 6. These 
findings suggested that day 2 to day 4 is the critical period in the SMC differentiation 
model. Based on this finding, most of the treatments in this project were carried out 
during this time period to investigate the mechanism by which miR-34a/SirT1 
regulate SMC differentiation. 
 
Furthermore, human ES cells were seeded on collagen coated flasks to examine 
whether collagen can stimulate SMC differentiation in vitro in a similar manner of 
that in mouse ES cells. Data from Figure 18A and B suggested that SMC specific 
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markers, including PDGFRB, were significantly up-regulated during upon collagen 
stimulation over 9 days. SMαA is one of the actins isoforms and major constituent of 
the contractile apparatus within SMCs. Immunofluorescence analysis from Figure 
18C established the presence of SMαA in differentiated SMCs from human ES cells, 
which has been further confirmed by flow cytometry analyses (Figure 18D). These 
data clearly suggests that Collagen can initiate SMC differentiation from both mouse 
and human ES cells.  
 
 
5.2 miR-34a and SMC differentiation 
Accumulating evidences suggest that microRNAs play an important role in 
biological regulation. As described before, Dicer and Drosha are essential for 
biogenesis of mature miRNAs. Recent studies using Dicer or Drosha deficient ES 
cells which were unable to generate mature miRNAs demonstrated that microRNAs 
can regulate self-renewal and differentiation of ES cells (Murchison et al., 2005, 
Wang et al., 2007). Some miRNAs, i.e. miR-21, has been identified to directly target 
Nanog and Sox2 which are key factors for maintaining stem cell functions 
(Murchison et al., 2005, Houbaviy et al., 2003).  
 
It has been reported that some miRNAs are involved in SMCs migration, 
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proliferation, phenotype switching and differentiation. Albinsson et al. (2010) 
reported that deletion of Dicer in vascular smooth muscle caused decreased SMC 
proliferation and differentiation, which suggested the important roles of miRNAs in 
VSMCs. Recently, miR-143 and miR-145 have been reported to play critical roles in 
SMC proliferation, phenotype switching and differentiation (Elia et al., 2009, Cordes 
et al., 2009, Cheng et al., 2009). Li et al. (2013a) reported that miR-638 inhibited 
SMC proliferation and migration through targeting Neuron-derived orphan receptor 1. 
However, the understanding of miRNAs in ES cells differentiation, especially in 
SMC differentiation is far from complete. 
 
To identify the potential miRNAs involved in SMC differentiation from ES cells, 
microRNA microarrays analysis was carried out on undifferentiated ES cells, 
differentiating ES cells (4 days in differentiation conditions) and differentiated ES 
cells (8 days in differentiation conditions) in this project. Among the increased 
miRNAs, miR-34a was significantly up-regulated during SMC differentiation (Table 
3), which was further confirmed by Real-Time PCR analysis (Figure 10), implying 
that miR-34a may also be involved in SMC differentiation.  
 
In mammalians, the miR-34 family comprises three processed miRNAs that are 
encoded by two different genes: miR-34a is encoded by its own transcript, and 
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miR-34b and miR-34c share a common primary transcript (Hermeking, 2010). In 
2007, several laboratories independently reported that members of the miR-34 family 
are direct p53 targets, and their up-regulation induces apoptosis and cell-cycle arrest 
(He et al., 2007, Raver-Shapira et al., 2007, Chang et al., 2007). Strikingly, the most 
highly enriched gene ontology category among the upregulated transcripts induced 
by miR-34a overexpression was ‘‘cell cycle’’ (Chang et al., 2007), which strongly 
indicates that miR-34a is a major player in the regulation of cell cycle progression. 
Considering cell cycle arrest or exiting from cell cycle progression is a critical 
process during cell differentiation, miR-34a could be a major regulator in cell 
differentiation from stem cells. In addition, similar to other p53-target genes, 
miR-34a may be an important regulator for other signaling pathways involved in 
normal embryos development, cell differentiation, apoptosis, senescence, 
proliferation and various diseases including cancer and cardiovascular diseases. 
Importantly, it has been recently reported that suppression of somatic cell 
reprogramming into pluripotent cells by miR-34a was at least in part due to 
repression of pluripotency genes, including Nanog, Sox2 and N-Myc (Choi et al., 
2011), which strongly suggests that miR-34a could play an important role in stem 
cell differentiation. Evidently, recent studies have suggested an important role of 
miR-34a in neural differentiation from neural stem cells (Aranha et al., 2011) and 
megakaryocytic differentiation from bipotent K562 human leukemia cells (Navarro 
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et al., 2009). miR-34a has also been identified as a critical cell-fate determinant in 
early-stage dividing colon cancer stem cells (Bu et al., 2013). However, the function 
role of miR-34a in SMC differentiation remains to be investigated. 
 
To explore the functional role of miR-34a in SMC differentiation, miR-34a 
gain/lost-function analyses were carried out in differentiating ES cells in vitro by 
using Pre-miR™ mmu-miR-34a miRNA Precursor, Anti-miR™ miR-34a inhibitor 
and siPORT™NeoFX™ transfection agent. Data from Figure 11A showed that 
miR-34a expression was significantly up-regulated by miR-34a precursor, and 
miR-34a inhibitor knockdown the expression of miR-34a during SMC differentiation 
(Figure 12A). More importantly, gene expression of SMαA, SM22α, calponin and 
SM-MHC were considerably increased upon miR-34a overexpression, while 
knockdown of miR-34a inhibited expression of these SMC specific markers Figure 
11A and Figure 12A). Protein level of SMαA and SM-MHC was also up-regulated 
by miR-34a overexpression and down-regulated by miR-34a inhibition, respectively 
(Figure 11B and Figure 12B). It has been reported that miR-145 is a well-known 
SMC differentiation related miRNA (Cheng et al., 2009, Cordes et al., 2009, Elia et 
al., 2009). Effect of miR-145 precursor or inhibitor on SMC differentiation was also 
included in the respective experiments as positive control for the functional 
involvement of miRNAs in SMC differentiation. As described earlier, SRF, 
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myocardin and MEF2c are well-established SMC transcriptional factors. Data from 
Figure 13 and Figure 14 demonstrated that the expression levels of these SMC 
transcription factors were also positively regulated by miR-34a, suggesting these 
molecules work in concert during SMC differentiation.  
 
Importantly, data shown in Figure 19 revealed that miR-34a over-expression 
significantly up-regulated, while miR-34a inhibition dramatically down-regulated 
SMC marker gene expressions in differentiating human ES cells, further 
demonstrating a critical role of miR-34a in mouse as well as human SMC 
differentiation from stem cells. 
 
 
Furthermore, control (pLL3.7-GFP) or miR-34a overexpressing (pLL3.7-GFP 
-miR-34a) ES cell line were generated by using respective lentivirus in this study to 
investigate the potential roles of miR-34a in in vivo SMC differentiation. The in vitro 
experiments with these cell lines (Figure 15A and Figure 15B) showed that the 
miR-34a level in miR-34a overexpressing ES cell was slightly higher than that of 
control cells at undifferentiated stage, but significantly increased after 8 days into 
SMC differentiation. Meanwhile more SMαA positive cells were detected in 
miR-34a overexpression cells compared with that in control cells (Figure 15C). The 
function of miR-34a during SMC differentiation in vivo was examined by using 
157 
 
miR-34a overexpressing ES cell lines combined with in vivo Martigel implantation 
model as described earlier. Data from Figure 16 showed that SM-MHC and GFP 
positive cells were detected in the Martigel implants, and miR-34a overexpressing 
ES cells generate more SM-MHC positive cells compare with that from control ES 
cell line, which indicated that these exogenous ES cells, especially miR-34a 
overexpressing ES cell line, successfully differentiated towards SMCs in vivo. SMC 
differentiation of ES cells in vivo was further confirmed by Real-Time PCR and 
Western blot analyses, and results showed that miR-34a overexpression significantly 
up-regulated the expression of SMC specific markers (Figure 17). 
 
Taken together, the results from this project provide clear evidence to support that 
miR-34a can regulate SMC markers expression in collagen induced SMC 
differentiation from both mouse and human ES cells in vitro. Also, by using miR-34a 
overexpressing cell lines and Martigel implantation, miR-34a was shown to play an 
important role in vivo. These observations clearly implied that miR-34a is a SMC 
differentiation regulator. 
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5.3 Up-regulation of SirT1 by miR-34a during SMC 
differentiation is a specific event 
By using computational algorithmic databases, SirT1 was predicted to be one of the 
top potential mRNA targets for miR-34a. Figure 21A showed two highly conserved 
binding sites for 5’ end of miR-34a were detected on 3’UTR of SirT1. It has been 
suggested that miR-34a regulates cell cycle progress and apoptosis in cancer cells by 
repressing its target gene SirT1 and forming a double positive feedback loop to 
regulate p53 activity (Yamakuchi et al., 2008, Yamakuchi and Lowenstein, 2009). 
Surprisingly, results from this project provided clear and solid evidence to suggest 
that rather than translational repression miR-34a regulates SirT1 in a translational 
activation manner, which likely represents a specific event between miR-34a and 
SirT1 during SMC differentiation from ES cell. 
 
Such notion has been supported by several lines of evidence: First, SirT1 gene 
expression and miR-34a expression were significantly activated during SMC 
differentiation from ES cells (Figure 20A and Figure 10). Secondly, SirT1 gene and 
protein expression levels were positively regulated by miR-34a overexpression 
experiments, but down-regulated by inhibition of miR-34a during SMC 
differentiation (Figure 20B and C). Also, inhibition or knockdown of SirT1 in 
differentiating ES cells significantly abolished the up-regulation of SMC specific 
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makers induced by miR-34a overexpression (Figure 31). Thirdly, the luciferase 
activity of wild type SirT1 3’ UTR reporter was significantly up-regulated by 
miR-34a overexpression, but such up-regulation was completely abolished when 
miR-34a binding sites were mutated, which suggested that binding between miR-34a 
and SirT1 is required for miR-34a mediated SirT1 regulation (Figure 21). Fourthly, 
the luciferase activity of ZEB1 or MECP2 3’UTR reporters, which containing 
binding site(s) for non-miR-34a miRNAs (MECP2 is the mRNA target for miR-22, 
and ZEB1 is the mRNA target for miR-200C/150, respectively), cannot be regulated 
by miR-34a (Figure 24). Finally SirT1 gene expression levels in the Matrigel 
implants with miR-34a overexpressing ES cells were much higher than that of 
Matrigel plugs implanted with control ES cells, suggesting that SirT1 gene 
expression level is also positively associated with miR-34a expression level during 
SMC differentiation from ES cells in vivo (Figure 16 and Figure 17). 
 
As described earlier, the classic thinking of miRNA regulation is that miRNAs bind 
to their target gene mRNAs and induce translational repression and/or degradation. 
The novel finding by which miR-34a positively regulates its target gene, SirT1, 
could be due to the following facts and/or observations:  
 
1. It has been reported that cell cycle regulation is closely associated with 
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differentiation of stem cell (Pauklin and Vallier, 2013, White and Dalton, 
2005). Figure 26 showed that differentiating ES cells undergo cell cycle arrest 
at G0/1 phase. As mentioned before, the miRNA-target gene regulatory 
machinery will switch from translation repression to activation when the cells 
have arrested at G0/1 phase and locked in quiescent cells (Vasudevan et al., 
2007, Vasudevan et al., 2008). Therefore, the findings that miR-34a positively 
regulates target gene SirT1 during SMC differentiation is consistent with their 
data.  
2. Another suggested criteria by Vasudevan et al. (2007) for miRNAs 
up-regulate their target genes is presence of AU-rich elements within 3’UTR 
of the target genes. By using free online search tool 
(http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi), similar to TNF-α we have 
found that SirT1 3’UTR is an A/U rich sequence (67%), and identified nearly 
11 AU rich elements (ARE) sites within 3’UTR of SirT1 (spanning through 
1000bps). More importantly, miR-34a binding site 2 is found to located 
closely with 8 of 11 ARE sites within SirT1 3’UTR (Figure 37).  
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Figure 37 The predicted ARE regions and miR-34 binding sites within mouse 
SirT1 3’UTR are depicted in this illustration 
   
 
3. While ES cells remain in undifferentiated stage, they have a shorter G1 phase 
as compared to differentiating ES cells. Interestingly, miR-34a negatively 
regulates SirT1 gene expression in undifferentiated ES cells, while positively 
regulates SirT1 gene expression in the terminally differentiated SMCs, as 
shown in Figure 23. 
4. Figure 28 showed that incubation of differentiating ES cells with 2µg/ml 
aphidicolin, a G0/G1 cell cycle arrest inducer, significant increased cell cycle 
arrest at G0/G1 phase, and such arrest was further enhanced by miR-34a 
overexpression. More importantly, aphidicolin could up-regulate SirT1 gene 
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reporter activity, and a synergetic effect between aphidicolin and miR-34a 
over-expression on SirT1 gene regulation was observed in this study. 
5. Removal of surrounding RNA sequence and structure of SirT1 3’UTR almost 
abolished the up-regulative effects of miR-34a on SirT1 3’UTR reporter 
activity (Figure 23). 
6. Significantly decreased incorporation of miR-34a and SirT1 RNA into 
Ago-RISC complex was observed upon SMC differentiation from RNA-IP 
experiment using antibody against Ago 2 (Figure 29). 
 
All these observations have provided a strong indication that miR-34a may positively 
regulate SirT1 gene expression through their binding sites within 3’UTR, which has 
been nicely proven by the finding that miR-34a binding site 2, rather than binding 
site 1, is required for miR-34a mediated SirT1 gene up-regulation (Figure 21). 
Results from this project also clearly suggests that up-regulation of SirT1 by 
miR-34a during SMC differentiation is a specific event (G0/G1 cell cycle arrest) 
between miR-34a and SirT1 gene during SMC differentiation, and both miR-34a 
binging sites and surrounding RNA sequence/structures within 3’UTR of SirT1 gene 
are required for such an event. 
 
Evidently, data from other studies also suggest that miRNAs can up-regulate their 
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target genes in other cell systems under normal cell culture condition. It has been 
reported that miR-155 directly and indirectly enhances its target gene TNF-α 
translation in macrophages (Tili et al., 2007), and miR-744 up-regulates CcnB1 
through the binding sites within gene promoter region in NIH/3T3 fibroblasts as well 
as TRAMP C1 cells (Huang et al., 2011). Place et al. (2008) reported that miR-373 
can target promoter sequences of E-cadherin and cold-shock domain-containing 
protein C2, and induces their gene expression. Additionally, miRNAs have also been 
suggested to up-regulate their target genes in immature oocytes (Mortensen et al., 
2011). 
 
5.4 SirT1 regulates SMC differentiation gene expression 
through a transcriptional mechanism  
One of novel mechanistic findings in the project is that SirT1 regulates SMC 
differentiation gene expression through a transcriptional mechanism. SirT1 is a 
member of the a NAD+-dependent class III group of histone deacetylases, and has 
been reported to be involved in a variety of biological systems and cellular functions, 
including obesity-associated metabolic diseases, cancer, aging, cellular senescence, 
cardiac aging and stress, prion-mediated neurodegeneration, inflammation, and 
placental cell survival (Yang et al., 2013). Importantly, recent data also suggests that 
SirT1 is a critical mediator in regulation of various development genes during stem 
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cell differentiation (Calvanese et al., 2010), and plays an important role in various 
cellular differentiations including endothelial progenitor cells (Cheng et al., 2012), 
hematopoietic cells (Ou et al., 2011), and osteoblasts (Srivastava et al., 2012).  
 
Results from this project provided clear evidence that SirT1 is an important SMC 
differentiation mediator by transcriptional regulation of SMC specific genes and 
transcriptional factors. Traditionally, SirT1 has mainly been linked to negative 
regulation of gene expression through deacetylation of histone and non-histone 
proteins (Tissenbaum and Guarente, 2001). However, accumulating evidence also 
strongly suggests that SirT1 can act both positively and negatively to control gene 
expression by recruiting a different set of coactivators and corepressors such as 
peroxisome proliferator–activated receptor γ coactivator-1α (Rodgers et al., 2005) or 
via a transcriptional mechanism (Chang and Guarente, 2013). In response to stress, 
activated SirT1 transcriptionally regulates its downstream target genes such as 
transcriptional factors (forkhead box Os and hypoxia-inducible factors-2α) and 
cardiac α-myosin heavy chain, through which SirT1 exerts a cardioprection response 
(Yang et al., 2013). In consistent with these findings, overexpression of SirT1 by 
using SirT1 overexpressing plasmids or SirT1 agonist in differentiating ES cells 
positively regulates expression of SMC specific makers (Figure 30). More 
importantly, data from Figure 34 and Figure 32B clearly indicated that SirT1 
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up-regulated promoter activities of SMC specific gene or transcriptional factors 
(SMαA, SM22α, SRF, MEF2c and myocd), which strongly demonstrated that SirT1 
is a transcription activator for SMC differentiation genes. Direct evidence for such 
transcriptional regulation of SMC specific genes was obtained from ChIP assays 
(Figure 33 and Figure 35A), in which the data revealed that SirT1 can directly bind 
to the promoter DNA of SMC specific genes and transcription factors. 
 
Another important finding of this project is that SirT1 acts as a potential 
transcriptional regulator for SMC gene regulation through modulating epigenetic 
modifications. It has been reported that SirT1 can induce the production of 
H3K9me3 in cultured U2OS cells (Vaquero et al., 2004) through directly interacting 
with deacetylating histone methyltransferase SUV39H1 (Vaquero et al., 2007). Data 
from Xiao et al. (2011) also suggested that H3K9 methylation was enriched within 
SMC specific gene promoters regions in the differentiating stem cells. H3K9me3 is 
well known for its repressive function in gene expression. Interestingly, data from 
Figure 36 revealed that instead of inducing H3K9me protein production, SirT1 
represses H3K9 tri-methylation status within SMC-specific gene promoters, resulting 
in SMC gene activation. However, the functional involvements of SirT1 in the 
regulation of other epigenetic modifications remain to be fully elucidated.  
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CHAPTER 6 Conclusion, limitations and 
future plans 
6.1 Conclusion  
SMC differentiation from pluripotent stem cell plays critical roles in cardiovascular 
system development, diseases and tissue engineering. Despite the enormous efforts 
have been put into this field in the past decade, our understandings of the molecular 
mechanisms underlying SMC differentiation are still far from complete. miRNAs are 
small non-coding RNAs and their important functions in biological regulation had 
not been correctly recognized till recent years. The individual miRNAs and their 
functional roles in SMC differentiation from pluripotent stem cell remains to be 
further elucidated.  
 
The present study have advanced our knowledge of the molecular mechanism 
mediating SMC differentiation by uncovering an important role of miR-34a in 
regulating SMC differentiation from mouse ES cells in vitro and in vivo, and 
provided compelling evidence to support the unexpected finding that miR-34a 
positively regulates its target gene SirT1 during SMC differentiation. This finding 
demonstrated that repression of SirT1 by miR-34a may switch to activation under 
specific conditions during the complex process of SMC differentiation, which 
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suggests that the “classical” miRNA-target genre repression regulatory machinery 
should be carefully considered under certain circumstance. Furthermore, the present 
study revealed that SirT1 regulates SMC gene expression through a transcriptional 
mechanism as well as an epigenetic signal pathway. Overall, the findings obtained 
from this study will significantly increase the understanding of the molecular 
mechanisms in SMC differentiation and benefit future application in regenerative 
medicine. 
 
6.2 Limitation and further work 
The limitation and further work are listed below: 
1. Without any doubts, miR-34a plays an important role in SMC differentiation 
as supported by the compelling evidence presented in this study, however the 
functional importance of miR-34a in embryonic SMC differentiation and 
cardiovascular system development are still unclear. To fully address such 
points, global and/or VSMC-specific miR-34a knockout mice/embryos are 
required. 
2. Results from this study revealed that miR-34a can also regulate SMC 
differentiation from human ES cells. However, the exact mechanism by 
which miR-34a regulates SMC differentiation from human ES cells needs to 
be further investigated. Also, data from the present study suggest that 
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miR-34a can up-regulate its target gene SirT1 during SMC differentiation 
from mouse ES cells, so experiments on human ES cells are required to 
investigate whether miR-34a can regulate SirT1 in a similar manner on 
human ES cells. 
3. Although various mechanisms by which how miR-34a up-regulates its target 
gene SirT1 have been nicely proposed and demonstrated in this study, 
additional molecular mechanisms which are potential responsible for SirT1 
up-regulation by miR-34a are possible existed and remain to be fully 
examined. For instance, whether RNA binding proteins are involved in 
up-regulation of SirT1 by miR-34a during SMC differentiation warranted for 
future investigation. 
4. SirT1 has been nicely demonstrated for the first time to regulate 
SMC-specific genes and transcription factors through direct binding to the 
promoter regions within respective genes, however the minimal essential 
binding elements of SirT1 or exact SirT1 binding motifs within these gene 
promoter regions remains to be further identified 
5. H3K9 trimethylation has been identified as one of mechanisms by which 
SirT1 regulates SMC differentiation gene expression, however,  its 
functional involvements in the regulation of other epigenetic modifications 
remain to be fully elucidated 
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6. The down-stream signal pathways by which how miR-34a mediates SMC 
differentiation from stem cells have been nicely elucidated, however, the 
up-stream pathway(s) about how and why miR-34a is activated during SMC 
differentiation is still lacking. 
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Chapter 7 Appendix and reference 
 
7.1 Appendix   
7.1.1Primer sets used in the project 
Gene names Forward (5’-3’) Reverse (5’-3’) Applicat
ion 
18s CCCAGTAAGTGCGGGTCATAA CCGAGGGCCTCACTAAACC Real-time 
RT-PCR 
U6 snoRNA gatgacacgcaaattcgtg miRNA universal reverse primer 
(Invitrogen, A11193-051) 
Real-time 
RT-PCR 
miR-34a (mu/hu) GGCAGTGTCTTAGCTGGTTGT miRNA universal reverse primer 
(Invitrogen, A11193-051) 
Real-time 
RT-PCR/RNA
-IP 
SMαA  TCCTGACGCTGAAGTATCCGAT GGCCACACGAAGCTCGTTATAG Real-time 
RT-PCR 
SM22α GAT ATG GCA GCA GTG CAG AG AGT TGG CTG TCT GTG AAG TC Real-time 
RT-PCR 
h1-Calponin  GGT CCT GCC TAC GGC TTG TC  TCG CAA AGA ATG ATC CCG TC Real-time 
RT-PCR 
SM-myh11  AAG CAG CCA GCA TCA AGG AG AGC TCT GCC ATG TCC TCC AC Real-time 
RT-PCR 
SMαA (hu) TGAGCGTGGCTATTCCTTCGT GCAGTGGCCATCTCATTTTCAA Real-time 
RT-PCR 
SM22α GGCTGAAGAATGGCGTGATT TCTGCTTGAAGACCATGGAGG Real-time 
RT-PCR 
h1-calponin  (hu) ATTTTTGAGGCCAACGACCTG CCCACGTTCACCTTGTTTCCT Real-time 
RT-PCR 
SM-myh11 (hu) GCGTCCATGCCAGATAACACA TACCACATCTCGCCCAACCTT Real-time 
RT-PCR 
PDGFR-β (hu) GCAATGTGACGGAGAGTGTGAA AGCAAATTGTAGTGTGCCCACC Real-time 
RT-PCR 
SRF CCTACCAGGTGTCGGAATCTGA TCTGGATTGTGGAGGTGGTACC Real-time 
RT-PCR 
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Myocd TCAATGAGAAGATCGCTCTCCG GTCATCCTCAAAGGCGAATGC Real-time 
RT-PCR 
MEF2C AAGCCAAATCTCCTCCCCCTAT TGATTCACTGATGGCATCGTGT Real-time 
RT-PCR 
SirT1 GCTCGCCTTGCGGTGGACTT GACGGCTGGAACTGTCCGGG Real-time 
RT-PCR/RNA
-IP 
SMαA-P1 CATAACGAGCTGAGCTGCCTC CCAAACAAGGAGCAAAGACG CHIP assay 
(with CArG 
region) 
SMαA-P2 GATCAGAGCAAGGGGCTATA CTACTTACCCTGACAGCGAC CHIP assay 
(without 
CArG 
region)  
SM22α-P1 GCAGGTTCCTTTGTCGGGCCA CTGCTTGGCTCACCACCCCG CHIP assay 
(with CArG 
region) 
SM22α-P2 CTTTAAACCCCTCACCCAGC ATGACTTGCACTTACAAGG CHIP assay 
(without 
CArG 
region)  
SRF-P_F2/R2 CCTGGCTGGCTTGGCACTCAC ATCTGGCCGGACGGTGTGATA CHIP assay 
SRF-P_F4/R4 CCCTCTTCTGCCCTGCAGTCCT CCGCGATTCCGTGGGAGGGA CHIP assay 
(Adjacent 
region) 
MEF2c-P_F1/R1 AGTCAGGACAGTGGCTTAGCGT CGGGTTAGTCTCTGACAGTGGACC CHIP assay 
MEF2c-P_F4/R4 GCTCCAGTGTGCGATGTGCCA TCCGCAGCAAGCCAGTTTCC CHIP assay 
(Adjacent 
region) 
Myocd-P_F1/R1 AGGCAGCCTGTTGTAGGCTCG GAGAGGAGGTGGAGCCCTGCT CHIP assay 
(Adjacent 
region) 
Myocd-P_F3/R3 CGGGAGTTGCAAGCCAACCCA TCCCCAGCTTACTGCAGGGCT CHIP assay 
pmiR-Luc-SirT1-W
T 
GGACTCACGCGTTGCTCCACCAGCAT
TGGGAACT 
CACCTGGAGCTCCTGCATTCTTTAG
TGTAGCC 
SirT1 3’UTR 
reporter clone 
pmiR-Luc-SirT1-B
S1mu 
CACCACAAAT GACTTTGAGA 
TGTGAATATG C 
G CATATTCACA TCTCAAAGTC 
ATTTGTGGTG 
miR-34a 
binding site 1 
mutation 
pmiR-Luc-SirT1-B
S2mu 
CCCAGTTAGG 
ACCATTGACTTTGGAGGAGA AAAG 
CTTT TCTCCTCCAAAGTCAATGGT 
CCTAACTGGG 
miR-34a 
binding site 2 
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mutation 
pmiR-Luc-SirT1-B
S1/2mu 
CACCACAAAT GACTTTGAGA 
TGTGAATATG C 
CCCAGTTAGG 
ACCATTGACTTTGGAGGAGA 
AAAG 
miR-34a 
binding site 1 
and 2 
combinational 
mutation 
SirT1 3’UTR 
miR-34a binding 
site 1 
GAGCCTGCATAGATCTTCACCA ACTCTCCCCAGTAGAAGTACCATT RNA-IP 
SirT1 3’UTR 
miR-34a binding 
site 1 
TGCATAAAATACCCAGTTAGGACCA GCACAAACACATCATGCAAATGG RNA-IP 
pmiR-Luc-miR-34a 
binding site 
GCCTATGAGC ACCGTCA 
CTAGTGCGCA 
TGCGCACTAG TGACGGT 
GCTCATAGGC 
Generation of 
miR-34a 
artificial 
binding site 
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7.1.2 Microarray data from miR-34a overexpression 
 
PROBE_ID GENE SYMBOL Fold changes ACCESSION PROTEIN_PRODUCT Comment
Up-regulation by miR-34a over-expression
ILMN_1221148 CNN1 5.622138271 NM_009922.3 NP_034052.2 h1-calponin
ILMN_2595612 Idh2 4.273697206 NM_173011.1 NP_766599.1
ILMN_1244099 LOC100041388 4.014480491 XM_001476627.1 XP_001476677.1
ILMN_2636803 Acyp2 4.003017615 NM_029344.3 NP_083620.1
ILMN_1249378 Bhlhb2 3.909017089 NM_011498.4 NP_035628.1
ILMN_1239370 Shfm1 3.745368624 NM_009169.2 NP_033195.1
ILMN_2764781 Pls3 3.615617528 NM_145629.1 NP_663604.1
ILMN_2971043 V1rd6 3.5419975 NM_030738.1 NP_109663.1
ILMN_2695964 Lep 3.440290865 NM_008493.3 NP_032519.1
ILMN_2641111 Dpagt1 3.275815373 NM_007875.2 NP_031901.2
ILMN_2671366 6330577E15Rik 3.117077402 NM_026377.1
ILMN_2599130 Aldoa 3.109562032 NM_007438.3 NP_031464.1
ILMN_2777986 Pck1 3.074604817 NM_011044
ILMN_1225414 Rab5c 2.914454097 NM_024456.2 NP_077776.2
ILMN_2462745 H2-D1 2.798198849 NM_010380.3 NP_034510.3
ILMN_2732848 TAGLN2 2.721118525 NM_178598.2 NP_848713.1 SM22alpha
ILMN_1245987 Hnrnpk 2.667151752 NM_025279.2 NP_079555.1
ILMN_2654296 Rab10 2.617282273 NM_016676.4 NP_057885.1
ILMN_2716838 Hspa4 2.350300909 NM_008300.3 NP_032326.3
ILMN_2691613 Ugcg 2.334163401 NM_031868.2 NP_114074.1
ILMN_2511089 Ppp1ca 2.300596168 NM_011673
ILMN_2747959 Dcn 2.195035137 NM_007833.4 NP_031859.1
ILMN_2607408 Pcbp4 2.178358316 NM_021567.2 NP_067542.2
ILMN_2873319 Lypla1 2.173443856 NM_008866.2 NP_032892.1
ILMN_2710354 ACTA2 2.1729868 NM_007392.2 NP_031418.1 SM α-actin
ILMN_2849521 Pycr1 2.169303834 NM_144795.2 NP_659044.1
ILMN_1218842 LOC381105 2.160453784 XM_355021.1
ILMN_2418957 5930418K15Rik 2.146499883
ILMN_1254883 Fip1l1 2.143354544 NM_024183.4 NP_077145.2
ILMN_2873822 AEBP1 2.079588497 NM_009636.1 NP_033766.1 aortic carboxypeptidase-like protein 
ILMN_2643159 SIRT1 2.051813061 NM_019812.1 NP_062786.1 sirtuin 1
ILMN_2978040 Myh8 2.028195488 NM_177369.3 NP_796343.2
ILMN_2876071 Fth1 2.020825185 NM_010239.1 NP_034369.1
ILMN_2621581 SMTN 1.980577874 NM_013870.2 NP_038898.1 smoothelin
ILMN_1231072 A630082K20Rik 1.958463745 XM_145254
ILMN_1218247 Palld 1.916824434 XM_974900.1 XP_979994.1
ILMN_2988299 SRF 1.91038159 NM_020493.1 NP_065239.1 Serum response factor
ILMN_1227803 LOC674707 1.860780338 XR_031381.1
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ILMN_2836982 DES 1.821677099 NM_010043.1 NP_034173.1 desmin
ILMN_2435360 MYOCD 1.820363166 NM_145136.4 NP_660118.3 myocardium
ILMN_2691780 Myl3 1.786516369 NM_010859.1 NP_034989.1
ILMN_2804261 CALD1 1.780141459 NM_145575.2 NP_663550.1 h-caldesmon
ILMN_2936221 Uprt 1.772344129 NM_001081189.1 NP_001074658.1
ILMN_2758452 Hn1 1.75919755 NM_008258.1 NP_032284.1
ILMN_1218347 MYLK 1.744983995 NM_139300.3 NP_647461.3 telokin
ILMN_2679063 Dctn2 1.735718025 NM_027151.1 NP_081427.1
ILMN_2622217 MYH11 1.723761875 NM_013607.1 NP_038635.1 smooth muscle myosin heavy chain 11
ILMN_1214950 MEF2C 1.719307738 NM_025282.2 NP_079558.1 myocyte enhancer factor 2C
ILMN_2533447 AA407270 1.71203639 NM_001033208.3 NP_001028380.1
ILMN_2518457 Irak1 1.708525698 NM_008363.2 NP_032389.2
ILMN_2643326 2210020M01Rik 1.685217224 NM_183259.2 NP_899082.1
ILMN_2699222 LOC669053 1.6652632 XM_972773.1 XP_977867.1
ILMN_1230140 LOC385923 1.659273047 XM_359000.1
ILMN_3133448 Mfge8 1.650499233 NM_001045489.1 NP_001038954.1
ILMN_2694955 Igfbp4 1.611891845 NM_010517.2
ILMN_1221235 4933425L21Rik 1.606305557 AK019858
ILMN_1235646 1110069O07Rik 1.587316809
ILMN_1234729 C130017I15Rik 1.582996786 AK047868
ILMN_2513536 Ythdf3 1.576358155 NM_172677.2 NP_766265.2
ILMN_1227357 Flot2 1.573381621 NM_008028.2 NP_032054.1
ILMN_1241039 2510042H12Rik 1.562091712 AK011092
ILMN_1239535 Plekhm2 1.560872256 XM_924800.3 XP_929893.3
ILMN_1212702 Hba-a1 1.547253336 NM_008218.2 NP_032244.2
ILMN_1213431 LOC626583 1.530697304 XM_988307.1 XP_993401.1
ILMN_2419138 VCL 1.501898958 NM_009502.4 NP_033528.3 metavinculin
Down-regulation by miR-34a over-expression
ILMN_3005211 Akap6 0.628808485 NM_198111.2 NP_932779.2
ILMN_1240938 AW212394 0.602759169 NM_133829
ILMN_2684370 Igk-C 0.589605323 XM_132633.4
ILMN_1213449 Man2c1 0.588938772 NM_028636.2 NP_082912.1
ILMN_2653617 Cd63 0.588478696 NM_007653.1
ILMN_1253322 Tex261 0.588088929 NM_009357.1 NP_033383.1
ILMN_1244081 Rgs4 0.582896009 NM_009062.3 NP_033088.2
ILMN_2744326 LOC665250 0.575666945 XR_033814.1
ILMN_1253970 Sirt7 0.575421788 NM_153056.1 NP_694696.1
ILMN_2791963 E2f6 0.563460644 NM_033270.1 NP_150373.1
ILMN_2867147 Tyrobp 0.562853185 NM_011662.2 NP_035792.1
ILMN_2714252 Kcnj3 0.557833702 NM_008426.1 NP_032452.1
ILMN_1256518 Akr7a5 0.551937352 NM_025337.2 NP_079613.2
ILMN_2752817 Myb 0.550583451 NM_010848.3 NP_034978.3
ILMN_2607529 LOC100046044 0.546925564 XM_001475459.1 XP_001475509.1
ILMN_1233283 P2rx5 0.543051384 NM_033321.1 NP_201578.1
ILMN_1243319 Trib2 0.54076479 NM_144551.5 NP_653134.2
ILMN_2626773 Rbak 0.533060729 NM_021326.2 NP_067301.1
ILMN_1254199 Gaa 0.532515968 NM_008064.2 NP_032090.2
ILMN_1235366 LOC100045628 0.53117846 XR_031850.1
ILMN_2510612 Ywhaz 0.530641568 NM_011740.2 NP_035870.1
ILMN_2628876 Jph2 0.528423701 NM_021566.1 NP_067541.1
ILMN_1215067 Ctbp1 0.526071557 NM_013502.2 NP_038530.1
ILMN_3090793 Nfyc 0.525698077 NM_008692.3 NP_032718.2
ILMN_2752994 Fbxo32 0.52354856 NM_026346.1 NP_080622.1
ILMN_2777474 H2-T23 0.519869076 NM_010398.1 NP_034528.1
ILMN_2457437 A830080H07Rik 0.519543217
ILMN_2537836 LOC385865 0.518471833 XM_358975.1
ILMN_2927025 Sdcbp 0.517597012 NM_016807.1 NP_058087.1
ILMN_1235635 Slco3a1 0.513386835 NM_023908.2 NP_076397.2
ILMN_2705268 Atp5l 0.512445091 NM_013795.4 NP_038823.2
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ILMN_2529932 LOC385905 0.427319747 XR_034995.1
ILMN_2710784 Gpsn2 0.426685111 NM_134118.3 NP_598879.1
ILMN_2618364 Flnc 0.426361591 NM_001081185.1 NP_001074654.1
ILMN_2715289 Exosc7 0.425933252 NM_001081188.1 NP_001074657.1
ILMN_2693976 Ncl 0.424817135 NM_010880.3 NP_035010.3
ILMN_1236828 Usp20 0.422404031 NM_028846.3 NP_083122.1
ILMN_1256369 Lynx1 0.419799355 NM_011838.4 NP_035968.1
ILMN_1249514 Large 0.415024023 NM_010687.1 NP_034817.1
ILMN_1226970 Wwp2 0.40899385 NM_025830.3 NP_080106.1
ILMN_2697918 LOC381302 0.408386585 XM_355244.1
ILMN_1255927 Ubtf 0.404891052 NM_001044383.1 NP_001037848.1
ILMN_1221168 2310061F22Rik 0.404598175 NM_153775.1 NP_722470.1
ILMN_2681030 EG629595 0.402452137 XM_894495.2 XP_899588.1
ILMN_1237183 Ociad1 0.381976204 NM_023429.3 NP_075918.1
ILMN_2713060 Fam131a 0.369421669 NM_133778.2 NP_598539.1
ILMN_2733356 Endod1 0.364638976 NM_028013.2 NP_082289.1
ILMN_1252204 Sepw1 0.364105606 NM_009156.2 NP_033182.1
ILMN_1250816 Apeh 0.363210275 NM_146226.1 NP_666338.1
ILMN_1244098 Dst 0.359134991 NM_134448.2 NP_604443.2
ILMN_2445548 C330006A16Rik 0.358698462
ILMN_1231542 Ttn 0.357513978 NM_011652.3 NP_035782.3
ILMN_1377923 Actb 0.353220505 NM_007393.3 NP_031419.1
ILMN_1254358 Igfbp5 0.348021168 NM_010518.2 NP_034648.2
ILMN_2527650 LOC268700 0.346186618 XM_193742.2
ILMN_3073318 Tom1l2 0.346158034 NM_153080.2 NP_694720.2
ILMN_2654074 Sesn1 0.345735691 NM_001013370.1 NP_001013388.1
ILMN_2994779 Gpsn2 0.340700999 NM_134118.1 NP_598879.1
ILMN_2480021 0610007P22Rik 0.339814991 NM_026676.2 NP_080952.1
ILMN_1232298 BC003940 0.335811448 NM_001033231.2 NP_001028403.1
ILMN_1377918 LOC100048105 0.335515669 XM_001479832.1 XP_001479882.1
ILMN_2611699 Jmjd1b 0.335403769 NM_001081256.1 NP_001074725.1
ILMN_2661005 1110018G07Rik 0.326283053 NM_178065.3 NP_835166.2
ILMN_2723881 Hcfc1 0.326241686 NM_008224.3 NP_032250.2
ILMN_2737658 Pdk2 0.326102669 NM_133667.1 NP_598428.1
ILMN_1219978 Appl2 0.325859192 NM_145220.2 NP_660255.1
ILMN_3128792 Ttn 0.316510794 NM_028004.2 NP_082280.2
ILMN_2704562 LOC100047628 0.316406947 XM_001476703.1 XP_001476753.1
ILMN_1244316 Hbb-b1 0.31627096 AK010993
ILMN_2621471 1110007L15Rik 0.31623635 NM_026269.1 NP_080545.2
ILMN_1214024 2310003M01Rik 0.315148721 AK009124
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ILMN_1232295 Sort1 0.509807516 NM_019972
ILMN_1227459 Gga2 0.508942236 NM_028758.2 NP_083034.1
ILMN_2425415 Ube3b 0.505632053 NM_054093.2 NP_473434.2
ILMN_1239729 Kif1b 0.504351203 NM_207682.2 NP_997565.2
ILMN_2620078 Dap3 0.501323496 NM_022994.2 NP_075370.1
ILMN_2589073 Lrrc10 0.500021345 NM_146242.2 NP_666354.1
ILMN_1227839 Brwd1 0.499482347 NM_145125.2 NP_660107.1
ILMN_2599110 Uspl1 0.498577121 NM_001013378.1 NP_001013396.1
ILMN_1238117 LOC386054 0.493252261 XM_359045.1
ILMN_2986315 Mir16 0.487658501 NM_019580.3 NP_062526.1
ILMN_1254987 Mbnl2 0.487128377 NM_175341.4 NP_780550.1
ILMN_2750428 Timm44 0.476772184 NM_011592.1 NP_035722.1
ILMN_1234324 Pdzd8 0.474702905 NM_001033222.2 NP_001028394.1
ILMN_2667447 Hdlbp 0.473999228 NM_133808.4 NP_598569.1
ILMN_1259528 LOC382092 0.469147057 XM_356174.1
ILMN_2739843 Metrn 0.467418561 NM_133719
ILMN_2993267 Keap1 0.465161445 NM_016679.2 NP_057888.1
ILMN_2971559 Eef1a2 0.465024364 NM_007906.2 NP_031932.1
ILMN_1257759 Tnrc6b 0.464889956 NM_144812.2 NP_659061.2
ILMN_2733046 Cdc25c 0.455919501 NM_009860.2 NP_033990.2
ILMN_1241915 Notch1 0.454971716 NM_008714.2 NP_032740.2
ILMN_2609948 Suds3 0.453359029 NM_178622.3 NP_848737.2
ILMN_1238313 Cnot2 0.452552762 NM_001037846.2 NP_001032935.1
ILMN_1247990 Purb 0.451824808 NM_011221.2 NP_035351.1
ILMN_1258682 Map2k2 0.451660818 NM_023138.3 NP_075627.2
ILMN_1220309 Cep63 0.451484232 NM_001081122.1 NP_001074591.1
ILMN_1247312 Kpna3 0.449438204 NM_008466.3 NP_032492.1
ILMN_2628875 Jph2 0.447043915 NM_021566.1 NP_067541.1
ILMN_1227926 Flt1 0.445619416 NM_010228.3 NP_034358.2
ILMN_1220498 Pygm 0.44414986 NM_011224.1 NP_035354.1
ILMN_2655260 Ptp4a3 0.442203662 NM_008975.2 NP_033001.2
ILMN_2930819 Acd 0.437936397 NM_001012638.1 NP_001012656.1
ILMN_2675785 Myo18b 0.433358207 XM_912851.3 XP_917944.3
ILMN_1221702 Plaa 0.432391343 NM_172695.2 NP_766283.2
ILMN_1246601 Glg1 0.431889168 NM_009149
ILMN_2724545 Sbk 0.431232234 NM_145587.1
ILMN_2813594 Zfp691 0.431018251 NM_183140.1 NP_898963.1
ILMN_2632665 Cav1 0.430594443 NM_007616.3 NP_031642.1
ILMN_2546596 2310076E21Rik 0.429992929 AK010195
ILMN_2656677 Fkbp8 0.429677397 NM_010223.1 NP_034353.1
ILMN_2739760 Prelp 0.428983401 NM_054077.3 NP_473418.2
ILMN_2499264 4933428A15Rik 0.42785664 NM_027756
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ILMN_1224045 Dsp 0.31458421 XM_621314.3 XP_621314.2
ILMN_2699028 Crybg3 0.314261164 NM_174848.2 NP_777273.1
ILMN_2740852 F2r 0.306318637 NM_010169.3 NP_034299.2
ILMN_2670713 Cyfip2 0.305397666 NM_133769.2 NP_598530.2
ILMN_2777798 EG667723 0.294813005 XM_001001948.1 XP_001001948.1
ILMN_2590961 Hadh 0.294489032 NM_008212.3 NP_032238.2
ILMN_1213609 Txnip 0.294044329 NM_023719.1 NP_076208.1
ILMN_1246808 Serpine2 0.285704085 AK045954
ILMN_2760295 BC003965 0.284864172 XM_128528.2
ILMN_2762056 Dtnbp1 0.264900509 NM_025772.3
ILMN_2710139 Ppargc1a 0.262055987 NM_008904.1 NP_032930.1
ILMN_2625981 Tcp11l2 0.252211623 NM_146008.2 NP_666120.1
ILMN_2591731 Ptprb 0.243202853 NM_029928.1 NP_084204.1
ILMN_2636335 Sfrs2 0.239533525 NM_011358.1 NP_035488.1
ILMN_2565729 B230386D16Rik 0.238450669 AK046451
ILMN_2607880 Tkt 0.236974973 NM_009388.2 NP_033414.1
ILMN_2771991 Ndrg2 0.236307041 NM_013864
ILMN_2538355 LOC386233 0.226558057 XM_359128.1
ILMN_2588056 LOC100042427 0.22620383 XM_001478518.1 XP_001478568.1
ILMN_2593694 Lrtm1 0.225907269 NM_176920.3 NP_795894.1
ILMN_2635082 LOC620009 0.223555458 XR_030609.1
ILMN_2747168 Ddx5 0.214385503 NM_007840.3 NP_031866.2
ILMN_2762863 AI606181 0.213847123 XR_035118.1
ILMN_2788673 Pgm2 0.213514628 NM_028132.2 NP_082408.2
ILMN_2806676 Acads 0.205321587 NM_007383.2 NP_031409.2
ILMN_2918987 Lias 0.203012732 NM_024471.2 NP_077791.1
ILMN_1249486 Mgl1 0.194652521 NM_010796.2 NP_034926.1
ILMN_3144820 LOC329575 0.194506015 NM_001024849.1 NP_001020020.1
ILMN_2712957 Prpf6 0.194453201 NM_133701.2 NP_598462.1
ILMN_2673024 Mrps24 0.192982414 NM_026080.2 NP_080356.1
ILMN_1219840 2310033F14Rik 0.18445462
ILMN_1237061 Dm15 0.183702219 NM_032418
ILMN_2764727 Actn2 0.174128023 NM_033268.2
ILMN_1236904 Mrpl23 0.164063753 NM_011288.1 NP_035418.1
ILMN_1215942 LOC381095 0.152240283 XM_358506.1
ILMN_1239040 mtDNA_CytB 0.112099942
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